<![CDATA[Last Week in Longevity]]>https://longevitybuilders.euhttps://longevitybuilders.eu/img/substack.pngLast Week in Longevityhttps://longevitybuilders.euSubstackSat, 16 May 2026 23:58:40 GMT<![CDATA[Last Week in Longevity #19 - $147M raised + EGYM merger]]>https://longevitybuilders.eu/p/last-week-in-longevity-19-147m-raisedhttps://longevitybuilders.eu/p/last-week-in-longevity-19-147m-raisedWed, 01 Apr 2026 15:34:23 GMT👋 Hi, I am Fabian, and welcome to my newsletter Last Week in Longevity. Every week, I track where the money, talent, and ideas are moving in the longevity business.

💸 Closed funding rounds

US$ 147M raised across 2 deals (⬇️ -51% vs. US$ 302M across 4 deals last week)


Direct Longevity Interventions (Category 1)

Gilgamesh Pharma – US$ 60M (Series A) | New York, USA

  • What they do: Developing novel neuropsychiatric therapeutics including oral NMDA receptor antagonist blixeprodil and AbbVie-partnered neuroplastogens for depression and anxiety. The company was spun off from the original Gilgamesh Pharmaceuticals after a licensing deal with AbbVie on psychiatric disorder candidate bretisilocin worth up to $1.2B.

  • Why it matters: Neuropsychiatric conditions like depression and anxiety are major drivers of reduced emotional and cognitive healthspan. Gilgamesh’s neuroplastogens aim to restore brain plasticity — a fundamental mechanism that declines with age and contributes to cognitive rigidity, treatment-resistant depression, and emotional deterioration in older adults.

  • Investors: Led by Satori Neuro; participation from Prime Movers Lab and existing institutional investors.

  • Valuation: unknown

  • Links: Fierce Biotech

Longevity-Aligned Disease Modification (Category 2)

Immutrin – US$ 87M (£65M) (Series A) | Cambridge, UK

  • What they do: Developing next-generation antibody therapies designed to deplete systemic amyloid deposits and reverse amyloidosis, with a lead program targeting ATTR (transthyretin) cardiomyopathy — a serious and progressive form of heart disease caused by misfolded protein aggregation.

  • Why it matters: Protein misfolding and amyloid accumulation are hallmarks of aging. ATTR cardiomyopathy is increasingly recognized as an underdiagnosed cause of heart failure in older adults. Immutrin’s approach to clearing existing amyloid deposits, rather than merely preventing new ones, could represent a breakthrough in reversing age-related organ damage.

  • Investors: Led by Frazier Life Sciences; joined by F-Prime, Qiming Venture Partners, SR One, Cambridge Innovation Capital and Cambridge Enterprise Ventures.

  • Valuation: unknown

  • Links: BioSpace

Want the full weekly funding database? Subscribe for free!

📰 Top longevity business news

Playlist and EGYM close US$ 7.5B merger — the largest fitness & wellness deal in history

  • What happened: Playlist (parent company of ClassPass, Mindbody, and Booker) and Munich-based EGYM have officially completed their merger, creating the world’s largest full-stack fitness and wellness operating system. The $7.5B deal, backed by $785M in new equity led by Affinity Partners (with Vista Equity Partners, Temasek, and L Catterton), unites AI-driven software, consumer booking platforms, smart training equipment, and corporate wellness under one roof. The combined company now reaches 40,000+ Mindbody-powered businesses, 88,000+ ClassPass venues, 20,000+ EGYM Wellpass employer partners, and 33,000+ EGYM-powered fitness locations across 30+ countries with over 3,000 employees and $800M+ in combined 2025 net revenue. (PR Newswire) (Athletech News)

  • Why it matters: EGYM CEO Philipp Roesch-Schlanderer framed the deal as “building a long-awaited bridge between fitness, wellness, and the healthcare market” — with a clear mission to shift from repair to prevention. By integrating smart training hardware, AI-personalized workout plans, and corporate wellness (EGYM Wellpass serves 20,000+ employers) with Playlist’s consumer discovery and booking infrastructure, the merged entity is positioned to make preventive exercise the default healthcare layer for millions. This is the strongest signal yet that preventive health infrastructure is attracting mega-cap capital and that the fitness industry’s future lies in longevity.

VITAL-H: US$ 38M trial to test whether three drugs can slow aging in humans

  • What happened: UT Health San Antonio is preparing one of the largest human trials aimed at testing whether rapamycin, semaglutide, and dapagliflozin can slow biological aging. The VITAL-H trial, backed by $38M in federal contract support through ARPA-H’s PROSPR program, will enroll 700–1,000 healthy adults aged 60–65 in South Texas. Participants will wear Oura rings and be tracked on intrinsic capacity — a WHO-developed metric measuring physical function, cognition, strength, and independence rather than simply counting years. (Longevity.Technology) (San Antonio Report)

  • Why it matters: This is the first large-scale, federally backed Phase 3 trial designed specifically to test whether existing, FDA-approved drugs can slow aging in healthy humans — not just treat disease. By using intrinsic capacity instead of lifespan as the primary endpoint, VITAL-H offers a realistic pathway to regulatory approval for anti-aging interventions within years, not decades. If any of the three arms show measurable results, it could fundamentally reshape how aging is classified and treated by the medical establishment.

Atrogi’s “exercise pill” ATR-258 enters human trial

  • What happened: Stockholm-based Atrogi AB has dosed the first subjects in an 8-week trial of its lead candidate ATR-258, a first-in-class oral therapy designed to mimic the benefits of physical exercise. The drug selectively targets the β2-adrenergic receptor in skeletal muscle to stimulate muscle growth and energy uptake while avoiding cardiac side effects. The study, led by Associate Professor Morten Hostrup at the University of Copenhagen, will evaluate the drug’s muscle physiological effects in overweight male volunteers. (Atrogi) (BriefGlance)

  • Why it matters: Current GLP-1 weight-loss drugs like semaglutide cause significant muscle loss alongside fat reduction — a critical problem for aging populations where sarcopenia already threatens independence. If ATR-258 can safely build and preserve muscle mass through an oral pill, it would fill the biggest gap in the metabolic health toolkit and become a natural complement to GLP-1 therapies. For the longevity field, an exercise mimetic that works in humans would be transformative.

Don’t want to miss any exclusive analysis? Subscribe for free!

🗓 Events & meetups (Europe-only)

Share this article with others who might benefit.

Share

💼 New Longevity jobs (Europe-only)

  • (Remote/EU) Multiple roles @ Axo Longevity like Head of Growth, Junior Data & BI Analyst, Graphic Designer, Copywriter, Creative Director. Europe’s first high-performance longevity platform (blood panels, AI health copilot).

👉 To see the full list of all Longevity jobs, visit our Job Board.

Keep building the future of longevity - one week at a time.
Fabian

P.S. Want your open positions or events to be featured? Just send them my way by replying to this email.

]]><![CDATA[Last Week in Longevity #18 - $302M raised]]>https://longevitybuilders.eu/p/last-week-in-longevity-18-302m-raisedhttps://longevitybuilders.eu/p/last-week-in-longevity-18-302m-raisedWed, 25 Mar 2026 16:37:58 GMT👋 Hi, I am Fabian, and welcome to my newsletter Last Week in Longevity. Every week, I track where the money, talent, and ideas are moving in the longevity business.

💸 Closed funding rounds

US$ 302M raised across 4 deals.

Direct Longevity Interventions (Category 1)

Gilgamesh Pharma – US$ 60M (Series A) | New York, USA

  • What they do: Developing novel neuropsychiatric therapeutics including oral NMDA receptor antagonists and neuroplastogens for depression and anxiety. Spun off from original Gilgamesh Pharmaceuticals after a licensing deal with AbbVie on psychiatric disorder candidate bretisilocin worth up to $1.2B.

  • Why it matters: Neuropsychiatric conditions like depression and anxiety are major drivers of reduced emotional and cognitive healthspan. Gilgamesh’s neuroplastogens aim to restore brain plasticity — a fundamental mechanism that declines with age and contributes to cognitive rigidity, treatment-resistant depression, and emotional deterioration in older adults.

  • Investors: Led by Satori Neuro; participation from Prime Movers Lab and existing institutional investors.

  • Valuation: unknown

Longevity-Aligned Disease Modification (Category 2)

Immutrin – US$ 87M (£65M) (Series A) | Cambridge, UK

  • What they do: Developing next-generation antibody therapies designed to deplete systemic amyloid deposits and reverse amyloidosis, with a lead program targeting ATTR (transthyretin) cardiomyopathy — a serious and progressive form of heart disease caused by misfolded protein aggregation.

  • Why it matters: Protein misfolding and amyloid accumulation are hallmarks of aging. ATTR cardiomyopathy is increasingly recognized as an underdiagnosed cause of heart failure in older adults. Immutrin’s approach to clearing existing amyloid deposits, rather than merely preventing new ones, could represent a breakthrough in reversing age-related organ damage.

  • Investors: Led by Frazier Life Sciences and F-Prime; joined by Qiming Venture Partners, SR One, Cambridge Innovation Capital and Cambridge Enterprise Ventures.

  • Valuation: unknown

Crossbow Therapeutics – US$ 77M (Series B) | USA

  • What they do: Developing next-generation T-cell engagers targeting peptide human leukocyte antigens (pHLA) on myeloid cancer cells, with lead candidate CBX-250 in Phase 1 for acute myeloid leukemia, CML, myelodysplastic syndromes, and chronic myelomonocytic leukemia.

  • Why it matters: Cancer is one of the most prevalent age-related diseases. T-cell engagers represent a new class of immunotherapy that could provide more tolerable treatments for blood cancers — critical for extending both lifespan and quality of life in aging populations.

  • Investors: Taiho Ventures, Arkin Bio Capital, Sixty Degree Capital, MPM BioImpact, Pfizer Ventures, BVF Partners, Polaris Partners, Eli Lilly, and others.

  • Valuation: unknown

R1 Therapeutics – US$ 77.5M (Series A) | Redwood City, USA

  • What they do: Advancing a first-in-class pan-phosphate transporter inhibitor (AP306) for patients with chronic kidney disease on dialysis who suffer from hyperphosphatemia — elevated phosphorus levels that cause bone and cardiovascular disease.

  • Why it matters: Chronic kidney disease is strongly age-associated, and hyperphosphatemia in dialysis patients accelerates vascular calcification and bone disease. AP306 is the only agent that blocks the “active” transport of phosphate, potentially offering superior efficacy with significantly lower pill burden compared to 60-year-old phosphate binder therapies — a meaningful improvement for older patients.

  • Investors: Led by Abingworth, F-Prime Capital and DaVita Venture Group; joined by Curie.Bio, SymBiosis and U.S. Renal Care.

  • Valuation: unknown

Want the full weekly funding database?
Subscribe for free!

Subscribe now

📰 Top longevity business news

ARPA-H commits US$ 144M to prove aging can be treated — Cambrian Bio receives US$ 30.8M — The U.S. government launched its PROSPR program, the most significant public bet yet on healthspan extension. Cambrian Bio was awarded $30.8M to advance a novel mTORC1-selective rapamycin analog; Linnaeus Therapeutics received $22M for repurposed oncology compounds. (Cambrian Bio)

Celularity pivots fully to longevity with US$ 35M license deal — Celularity (NASDAQ: CELU) licensed its biomaterials portfolio for up to $35M and will concentrate all resources on placental-derived cell therapies targeting cellular senescence, chronic inflammation, and tissue degeneration. (Longevity.Technology)

Eli Lilly & Roche commit nearly US$ 1B to South Korea as longevity hub — Lilly signed a $500M MoU with South Korea’s Ministry of Health to expand Lilly Gateway Labs for biotech startups in collaboration with Samsung Biologics. Combined with Roche’s $480M commitment, nearly $1B is flowing into South Korea’s longevity ecosystem. (Longevity.Technology)

Don’t want to miss any exclusive analysis?
Subscribe for free!

Subscribe now

🗓 Events & meetups (Europe-only)

💼 New Longevity jobs (Europe-only)

  • You have an open position? Let us know!

👉 To see the full list of all Longevity jobs, visit our Job Board.

Keep building the future of longevity - one week at a time.
Fabian

P.S. Want your open positions or events to be featured? Just send them my way by replying to this email.

]]><![CDATA[Last Week in Longevity #17 - $218M raised]]>https://longevitybuilders.eu/p/last-week-in-longevity-17-218m-raisedhttps://longevitybuilders.eu/p/last-week-in-longevity-17-218m-raisedThu, 04 Dec 2025 18:18:13 GMT👋 Hi, I am Fabian, and welcome to my newsletter Last Week in Longevity. Every week, I track where the money, talent, and ideas are moving in the longevity business.

💸 Closed funding rounds

US$ 218M raised across 7 deals (⬇️ -57% vs. US$ 508M across 6 deals last week)


Direct Longevity Interventions (Category 1)

MitoRx Therapeutics – US$ 5.5M (Seed) | Oxford, UK

  • What they do: Developing small-molecule therapies that protect and repair mitochondria to treat metabolic diseases and obesity.

  • Why it matters: Mitochondrial dysfunction is a hallmark of aging. By improving mitochondrial efficiency and energy metabolism, MitoRx targets one of the core upstream levers of healthspan extension.

  • Investors: Led by Oxford Science Enterprises; participation from London Technology Club, Harrington Discovery Institute, and MEIF Proof-of-Concept & Early Stage Fund.

  • Valuation: unknown

  • Links: Company | Article

General Control Biotechnologies – amount undisclosed | Copenhagen, Denmark

  • What they do: Develops programmable biologic “control systems” designed to modulate core aging pathways with high specificity, enabling targeted slowing or reversal of biological aging.

  • Why it matters: This is one of the clearest moves yet by a major pharma company (Novo Nordisk) into true mechanism-of-aging drug development. GCB’s programmable platform could unlock a new generation of precision anti-aging therapies that intervene upstream of age-related disease, rather than treating symptoms downstream.

  • Investors: Backed by Novo Nordisk’s Bio Innovation Hub; additional investors undisclosed.

  • Valuation: unknown

  • Links: Company | Article

Longevity-Aligned Disease Modification (Category 2)

MindImmune Therapeutics – US$ 10.2M (Series A extension) | Providence, USA

  • What they do: Developing drugs that modulate neuroinflammation by targeting overactive immune cells in the brain to treat Alzheimer’s and other neurodegenerative diseases.

  • Why it matters: Neuroinflammation is a key driver of cognitive decline. Reducing it could delay neurodegenerative onset and preserve brain function well into later life.

  • Investors: Led by Dolby Family Ventures; joined by ElevateBio, the Alzheimer’s Drug Discovery Foundation (ADDF), Slater Technology Fund, and other private investors.

  • Valuation: unknown

  • Links: Company | Article

Circular Genomics – US$ 15M (Series A) | Albuquerque, USA

  • What they do: Uses circular RNA biomarkers to diagnose and monitor neurodegenerative and psychiatric disorders, with Alzheimer’s as lead indication.

  • Why it matters: Enables earlier and more precise detection of Alzheimer’s, allowing timely intervention before irreversible neuronal damage — a critical step in extending cognitive healthspan.

  • Investors: Led by Mountain Group Partners; joined by UNM Rainforest Innovations and other institutional investors.

  • Valuation: unknown

  • Links: Company | Article

Protego Biotherapeutics – US$ 75M (Series B) | Cambridge, USA

  • What they do: Develops antibodies to clear misfolded light-chain proteins that cause amyloidosis and cardiac damage.

  • Why it matters: Protein misfolding and aggregation are fundamental aging mechanisms. Therapeutics preventing systemic amyloidosis could extend organ function and lifespan.

  • Investors: Led by MPM BioImpact; joined by Novo Holdings, Sofinnova Partners, F-Prime Capital, and Polaris Partners.

  • Valuation: unknown

  • Links: Company | Article

Zetagen Therapeutics – US$ 52M (Series C) | Syracuse, USA

  • What they do: Advances bone-regenerative and anti-metastatic compounds for skeletal diseases and bone loss from cancer.

  • Why it matters: Bone loss and metastatic fragility are major causes of late-life morbidity. ZetaMet’s platform could help maintain skeletal integrity, mobility, and resilience during aging.

  • Investors: Not specified in the article; prior rounds included Accelerate NY and Excell Partners.

  • Valuation: unknown

  • Links: Company | Article

Phrontline Biopharma – US$ 60M (Pre-A) | Shanghai, China

  • What they do: Developing bispecific and dual-payload antibody-drug conjugates (ADCs) for solid tumors.

  • Why it matters: Novel ADCs could make cancer treatment more precise and tolerable—vital for extending both lifespan and quality of life in aging populations.

  • Investors: Participating investors include Gaorong Capital, Hillhouse Capital, Legend Capital, and others.

  • Valuation: unknown

  • Links: Company | Article

Want the full weekly funding database? Subscribe for free!

🗓 Events & meetups (Europe-only)

Share this article with others who might benefit.

Share

💼 New Longevity jobs (Europe-only)

  • You have an open position? Let us know!

👉 To see the full list of all Longevity jobs, visit our Job Board.

Keep building the future of longevity - one week at a time.
Fabian

P.S. Want your open positions or events to be featured? Just send them my way by replying to this email.

]]><![CDATA[Last Week in Longevity #16 - $508M raised + €500M new dry powder]]>https://longevitybuilders.eu/p/last-week-in-longevity-16-508m-raisedhttps://longevitybuilders.eu/p/last-week-in-longevity-16-508m-raisedTue, 25 Nov 2025 18:01:26 GMT👋 Hi, I am Fabian, and welcome to my newsletter Last Week in Longevity. Every week, I track where the money, talent, and ideas are moving in the longevity business.

💸 Closed funding rounds

US$ 508M raised across 6 deals (↗️ +17% vs. US$ 434M across 9 deals last week)


Direct Longevity Interventions (Category 1)

Function Health – US$ 298M (Series B) | Austin, USA

  • What they do: Membership platform for large-panel lab testing (160+ biomarkers twice per year), plus MRI/CT scanning and an AI “Medical Intelligence Lab” that turns this data into personalised health insights.

  • Why it matters: Function is currently one of the most scaled, consumer-facing implementations of comprehensive prevention: biomarker panels, whole-body imaging, and a longevity narrative around “owning your health”. A serious contender for the default health operating system of many consumers.

  • Investors: Redpoint Ventures (lead), Andreessen Horowitz (a16z), Aglaé Ventures, Alumni Ventures, Battery Ventures, and many more.

  • Valuation: US$ 2.5B post-money

  • Links: Company | Article

Holo – €1M (Pre-Seed) | Barcelona, Spain

  • What they do: Consumer preventive-health platform combining comprehensive lab testing (>110 biomarkers), wearable data and functional-medicine physicians into a personalised “health graph” and longevity programmes.

  • Why it matters: This is classic structured prevention: repeat biomarkers + longitudinal tracking + clinical oversight to catch risks before symptoms show and guide lifestyle changes. If they execute well (UX, adherence, medical quality), this is exactly the kind of “Revolut of health” infrastructure that can normalise proactive longevity care in Europe, especially for younger, tech-savvy consumers.

  • Investors: Calm/Storm Ventures (lead), Mission VC, ENISA, plus a long list of angels..

  • Valuation: Unknown.

  • Links: Company | Article

Longevity-Aligned Disease Modification (Category 2)

Aspen Neuroscience – US$ 115M (Series C) | San Diego, USA

  • What they do: Autologous iPSC-derived neuron replacement therapies for Parkinson’s disease and other neurodegenerative indications, using a patient’s own cells to restore dopamine function and rebuild neural circuits.

  • Why it matters: Neurodegeneration is one of the hardest late-life burdens – once neurons are gone, there’s usually no way back. If Aspen’s cell replacement can safely reverse motor symptoms and slow progression, it could meaningfully extend functional healthspan and independence for Parkinson’s patients, with spill-over into other CNS diseases. It’s a high-risk, high-reward bet directly on “rebuilding” aged brains rather than just managing symptoms.

  • Investors: Co-led by OrbiMed, ARCH Venture Partners, Frazier Life Sciences, Revelation Partners; participation from new investors Kite, a Gilead company, and Balyasny Asset Management

  • Valuation: Unknown.

  • Links: Company | Article

Okami Medical – US$ 45M | Aliso Viejo, USA

  • What they do: Develops vascular occlusion systems – minimally invasive embolisation devices using proprietary technology to rapidly occlude peripheral vessels in a “one-and-done” procedure.

  • Why it matters: Vascular disease and interventional radiology procedures are a huge part of older-adult medicine. Faster, more reliable embolisation means better control of bleeding, aneurysms and malformations, potentially fewer complications and shorter hospital stays. It’s not targeting aging biology, but it directly improves survival and quality-of-life in age-linked vascular conditions, so it fits squarely into longevity-aligned disease modification.

  • Investors: Growth financing from Gilde Healthcare and existing backers including Vensana Capital and U.S. Venture Partners (USVP).

  • Valuation: Unknown.

  • Links: Company | Article

AI Proteins – US$ 41.5M (Series A) | Boston, USA

  • What they do: Uses AI-driven de novo design to create programmable “miniprotein” biologics from scratch, aiming for safer and more precise protein therapeutics across oncology, metabolic and inflammatory diseases.

  • Why it matters: From a longevity perspective, AI Proteins is a platform bet on better drugs for the diseases that actually kill people in mid- to late-life: cancer, diabetes, cardiovascular/inflammatory conditions. De novo miniproteins may hit targets with higher specificity and better pharmacology than antibodies, which could translate into disease control with fewer side effects and longer, healthier lives. It’s downstream of aging, but if even a few of these programmes succeed, the impact on late-life morbidity could be substantial.

  • Investors: Mission BioCapital and Santé Ventures (co-leads); participation from Lightchain Capital, Cobro Ventures and others.

  • Valuation: Unknown.

  • Links: Company | Article

Longevity Enablers (Category 3)

Lumia – US$ 7M (Funding) | Boston, USA

  • What they do: Smart earrings (“Lumia 2”) that continuously track blood flow to the head plus standard wearable metrics (sleep, temperature, cycle, readiness), originally developed for POTS/Long-COVID patients and now offered as a general consumer wearable.

  • Why it matters: You can read this as “next-gen continuous hemodynamic monitoring in a consumer form factor”. Blood-flow dynamics are tightly linked to orthostatic intolerance, cognitive performance, and potentially cerebrovascular risk. A device people actually wear 24/7 that quantifies these patterns could become a powerful longevity enabler – catching dysautonomia, overtraining, or cardiovascular issues earlier and driving better lifestyle adherence. It’s still non-medical and early, but conceptually it pushes wearables closer to meaningful physiology, not just steps and HR.

  • Investors: J2 Ventures, BonAngels Venture Partners, plus angel investors

  • Valuation: Unknown.

  • Links: Company | Article

Want the full weekly funding database? Subscribe for free!

📰 Top longevity business news

Medicxi raises €500M to fuel next wave of global biotech innovation

  • What happened:
    Medicxi announced a new €500 million fund dedicated to early- and mid-stage biotech companies across Europe and the US, with a clear interest in age-related diseases and platform technologies. Read more here.

  • Why it matters:

    • This is one of the largest European funds dedicated to biotech this year, injecting much-needed capital into a tightening venture market.

    • For longevity founders, this signals a shift toward “quality over quantity”. Medicxi tends to pick companies with clear translational paths, raising the bar for scientific and commercial rigour.

Don’t want to miss any exclusive analysis? Subscribe for free!

🗓 Events & meetups (Europe-only)

Share this article with others who might benefit.

Share

💼 New Longevity jobs (Europe-only)

👉 To see the full list of all Longevity jobs, visit our Job Board.

Keep building the future of longevity - one week at a time.
Fabian

P.S. Want your open positions or events to be featured? Just send them my way by replying to this email.

]]><![CDATA[Last Week in Longevity #15 - $434M raised + fewer longevity moonshots]]>https://longevitybuilders.eu/p/last-week-in-longevity-15-434m-raisedhttps://longevitybuilders.eu/p/last-week-in-longevity-15-434m-raisedTue, 18 Nov 2025 20:17:13 GMT👋 Hi, I am Fabian, and welcome to my newsletter Last Week in Longevity. Every week, I track where the money, talent, and ideas are moving in the longevity business.

💸 Closed funding rounds

US$ 434M raised across 9 deals (↘️ -5% vs. US$ 459M across 7 deals last week)


Direct Longevity Interventions (Category 1)

NextSense – US$ 16M (Series A) | Mountain View, USA

  • What they do: Builds Smartbuds, the first truly wireless earbuds with clinical-grade EEG sensors that continuously monitor brain activity and use adaptive audio to deepen sleep, improve restoration, and enhance focus.

  • Why it matters: High-quality slow-wave sleep is one of the most powerful upstream levers on cardiometabolic, immune, and brain aging. If NextSense can make closed-loop sleep optimisation as mainstream as step counting, it’s a direct lifestyle intervention that scales across millions of people.

  • Investors: Round led by Ascension Ventures, with participation from Satori Neuro, Corundum Neuroscience Fund, and angels including David Eagleman, Esther Dyson, Bradley Horowitz, and others.

  • Valuation: unknown

  • Links: Company | Article

Renewal Bio – US$ (undisclosed amount) | Rehovot, Israel

  • What they do: Renewal Bio develops synthetic embryo-derived tissue platforms (“stembryos”) to generate functional cells and tissues for regenerative therapies, including applications in age-related organ failure and immune rejuvenation.

  • Why it matters: If scalable and safe, synthetic embryo-derived tissues are about as upstream as it gets: they promise replacement parts for aging organs rather than incremental symptom control. That’s squarely in the “repair the damage of aging” bucket and directly targets multiple age-related diseases at once (bone marrow, immune system, organ failure).

  • Investors: YZi Labs (first biotech investment) plus undisclosed co-investors.

  • Valuation: unknown

  • Links: Company | Article

Longevity-Aligned Disease Modification (Category 2)

Solve Therapeutics – US$ 120M | San Diego, USA

  • What they do: Solve Therapeutics develops next-generation antibody–drug conjugates (ADCs) for solid tumors using its CloakLink™ hydrophilic linker platform, aiming to improve pharmacokinetics, stability and safety compared to conventional ADCs.

  • Why it matters: Solid tumors (lung, breast, GI, etc.) are still among the biggest killers in later life. Better-tolerated, more precise ADCs that work in difficult solid tumors are clearly longevity-relevant: they extend survival and can preserve quality of life if toxicity and off-target damage are reduced.

  • Investors: Led by Yosemite; new investors Abingworth, Ally Bridge Group, B Capital, Balyasny Asset Management, Merck & Co., SymBiosis

  • Valuation: unknown

  • Links: Company | Article

Artios Pharma – US$ 115M (Series D) | Cambridge, UK / New York, USA

  • What they do: Artios is a DNA damage response (DDR) oncology company advancing an ATR inhibitor (alnodesertib) and a Polθ inhibitor (ART6043) for ATM-negative cancers (e.g. pancreatic, colorectal) and BRCA-mutant breast cancer, plus a DDR-ADC program.

  • Why it matters: Targeting DDR in specific genetic contexts aims to selectively kill tumor cells while sparing healthy tissue. That’s especially relevant in older patients who can’t tolerate broad cytotoxic regimens. If Artios’ drugs can turn lethal late-stage cancers into controllable diseases with less collateral damage, that’s directly extending healthy years.

  • Investors: Co-led by SV Health Investors and RA Capital Management; participation from Janus Henderson Investors, Andera Partners, Avidity Partners, EQT Life Sciences, Invus, IP Group, M Ventures, Novartis Venture Fund, Omega Funds, Pfizer Ventures, Piper Heartland, Schroders Capital, Sofinnova Partners and others.

  • Valuation: unknown

  • Links: Company | Article

Gate Bioscience – US$ 65M (Series B) | South San Francisco, USA

  • What they do: Gate Bioscience creates “molecular gate” drugs, degrader-like biologics targeting secreted and extracellular disease proteins, for indications in immunology and oncology.

  • Why it matters: A large fraction of late-life morbidity is driven by chronic inflammation and cancer. If Gate can safely clear or silence pathological secreted factors (think cytokines, growth factors) with high specificity, it could deliver longer, healthier lives via better control of autoimmune disease and cancer progression.

  • Investors: Led by SR One and Andreesen Horowitz

  • Valuation: unknown

  • Links: Company | Article

Scripta Therapeutics – US$ 12M (Seed) | Oxford, UK

  • What they do: Scripta Therapeutics is building a small-molecule discovery platform focused on modulating transcription factors, aiming at disease-modifying treatments for chronic conditions where gene expression programs drive pathology (e.g. neurodegeneration, immunology).

  • Why it matters: Durable, upstream control of transcription factors could shift disease trajectories rather than just treating downstream symptoms. For age-related neuro or immune diseases, that’s squarely longevity-aligned, potentially slowing or reversing progression over many years.

  • Investors: Oxford Science Enterprises (OSE) and Apollo Health Ventures, with further investment from AlbionVC, YZR Capital, and Parkwalk Advisors, and support from Oxford University Innovation

  • Valuation: unknown

  • Links: Company | Article

Modulight Biotherapeutics – US$ 12M (Seed) | Boston, USA

  • What they do: Modulight Biotherapeutics is developing an optogenetic neuromodulation platform (light-activated therapies delivered via implanted devices) to treat chronic neurological disorders, including chronic pain and movement disorders such as Parkinson’s and dystonia.

  • Why it matters: Chronic pain and neurodegenerative movement disorders are major drivers of late-life disability, polypharmacy, and reduced activity. A more precise, device-driven neuromodulation approach could reduce systemic drug burden, improve function, and keep patients independent longer.

  • Investors: Lead by Jibe Ventures and LocalGlobe, with participation from Nexus Neurotech Ventures, RedSeed VC, Secret Chord Ventures, Fresh Fund, Saras Capital, SilverArc Capital and Sha’ar Mivnim

  • Valuation: unknown

  • Links: Company | Article

Skeletalis – US$ 8M | Boston, USA

  • What they do: Skeletalis is building a bone-targeted small-molecule platform (OASIS™) starting with a locally activated osteoporosis drug designed to prevent fractures and preserve bone mineral density while minimising systemic side-effects.

  • Why it matters: Osteoporosis is a classic age-related condition: fractures in older adults drive disability, loss of independence and excess mortality. A safer, bone-targeted therapy that patients can stay on for years would directly extend functional healthspan, particularly for post-menopausal women.

  • Investors: Pillar VC (lead), KdT Ventures, age1, Slocum Management

  • Valuation: unknown

  • Links: Company | Article

Longevity Enablers (Category 3)

Beacon Biosignals – US$ 86M (Series B) | Boston, USA

  • What they do: Builds an AI-driven electroencephalogram (EEG) analytics platform and wearable EEG devices to generate high-resolution brain biomarkers, supporting drug development and clinical care in sleep, epilepsy, neurodegeneration and psychiatric disorders.

  • Why it matters: We’re desperately short of objective, scalable central nervous system biomarkers, which slows trials and obscures early disease. Beacon’s platform is exactly the kind of measurement layer needed to (a) de-risk brain-targeted longevity drugs and (b) give clinicians early warning and progress tracking in real-world patients.

  • Investors: Series B led by Innoviva, with participation from GV, Nexus NeuroTech Ventures, S32, Catalio Capital Management, Takeda Ventures, and existing investors including General Catalyst, Casdin Capital, Logos Capital, Global Brain.

  • Valuation: Unknown

  • Links: Company | Article

Want the full weekly funding database? Subscribe for free!

📰 Top longevity business news

Longevity startup funding: fewer moonshots, but plenty of investments

  • What happened:
    Venture capital for longevity-focused startups is still flowing, but the size of deals has come down from the “mega-round” era; the biggest 2025 round identified was ~$130 m. Read more here.

  • Why it matters:

    • It signals a recalibration of investor expectations in the longevity sector: fewer ultra-high risk bets (apart from drug development), more disciplined capital deployment.

    • For entrepreneurs and investors it means the bar is getting higher: bigger proof-points needed before large rounds, meaning earlier-stage companies need to show more tangible milestones.

    • It also indicates that the longevity space is maturing – moving from hype to execution. That’s good for long-term stability, though it may compress near-term upside for risk investors

AstraZeneca bolsters obesity portfolio with muscle-preserving buy

  • What happened:
    AstraZeneca acquired SixPeaks Bio with US$170 m upfront + up to US$130 m in milestones to add muscle preservation during weight-loss to its obesity therapies pipeline. Read more here.

  • Why it matters:

    • The global obesity market is massive (US$30 bn) and has major overlap with longevity: better metabolic/weight health = longer healthy lifespan.

    • It is the perfect addition to GLP-1s, often claimed to be the first longevity blockbuster drug.

Don’t want to miss any exclusive analysis? Subscribe for free!

🗓 Events & meetups (Europe-only)

Share this article with others who might benefit.

Share

💼 New Longevity jobs (Europe-only)

👉 To see the full list of all Longevity jobs, visit our Job Board.

Keep building the future of longevity - one week at a time.
Fabian

P.S. Want your open positions or events to be featured? Just send them my way by replying to this email.

]]><![CDATA[Last Week in Longevity #14 - $459M raised + Biotech Funding Winter]]>https://longevitybuilders.eu/p/last-week-in-longevity-14-459m-raisedhttps://longevitybuilders.eu/p/last-week-in-longevity-14-459m-raisedTue, 11 Nov 2025 15:31:59 GMT👋 Hi, I am Fabian, and welcome to my newsletter Last Week in Longevity. Every week, I track where the money, talent, and ideas are moving in the longevity business.

💸 Closed funding rounds

US$ 459.4M raised across 7 deals (↗️ +138% vs. US$ 193M across 5 deals last week)


Direct Longevity Interventions (Category 1)

(none)

Longevity-Aligned Disease Modification (Category 2)

Braveheart Bio – US$ 185M (Series A) | USA

  • What they do: Cardiac myosin inhibitor BHB-1893 for hypertrophic cardiomyopathy (HCM), in-licensed from Hengrui; aims for best-in-class efficacy/simplicity vs. Camzyos.

  • Why it matters: HCM is a serious, often age-diagnosed heart disease; better, safer myosin inhibition could reduce heart-failure progression and events, directly extending healthy life for a sizable population.

  • Investors: Round includes Andreessen Horowitz, Forbion, OrbiMed and others

  • Valuation: unknown

  • Links: Company | Article

AAVantgarde Bio – US$ 141M (Series B) | Milan, Italy

  • What they do: AAV gene therapy addressing root genetic causes of Stargardt disease (ABCA4) and Usher 1B retinitis pigmentosa.

  • Why it matters: Vision loss is a major driver of disability in aging. Disease-modifying gene therapy that preserves or restores sight materially improves functional healthspan and independence.

  • Investors: Co-led by Schroders Capital, Atlas Venture, and Forbion.

  • Valuation: unknown.

  • Links: Company | Article

Azalea Therapeutics – US$ 82M (Seed + Series A) | Berkeley, USA

  • What they do: In-vivo precision genome engineering that directly creates CAR-T and other cell therapies inside the patient, combining EDV delivery + AAV templates.

  • Why it matters: If in-vivo CAR-T works safely, it could massively expand access to curative-intent cell therapies in cancer/autoimmunity with fewer toxic conditioning steps, no ex-vivo manufacturing, and potentially more durable disease control, improving late-life healthspan.

  • Investors: Led by Third Rock Ventures, with participation from RA Capital, Yosemite, Sozo Ventures, and selected angels.

  • Valuation: unknown

  • Links: Company | Article

Onchilles Pharma – US$ 25M (Series A1) | San Diego, USA

  • What they do: ELANE-pathway cytotoxic biologic N17350 that selectively kills tumors and activates immunity; moving to first-in-human.

  • Why it matters: If the ELANE approach translates in clinic, it promises broad, tumor-selective killing with immune memory, potentially improving survival and lowering toxicity vs. conventional chemo.

  • Investors: Invivium Capital, Kennedy Lewis Investment Management, UCM Ventures; existing: LYZZ Capital Advisors, Lincoln Park Capital.

  • Valuation: unknown

  • Links: Company | Article

Accipiter Biosciences – US$ 12.7M (Seed) | Seattle, USA

  • What they do: De-novo designed multifunctional protein therapeutics (agonists & multispecifics) for immunology/oncology; deals with Pfizer (>$330M milestones) & Kite.

  • Why it matters: Complex, multimechanistic biologics could improve efficacy/safety in hard diseases (autoimmune, cancer), unlocking disease control that preserves late-life function.

  • Investors: Co-led by Takeda & Flying Fish Partners; with Columbus Venture Partners, Cercano Capital, Washington Research Foundation, Alexandria, Pack Ventures, Argonautic Ventures.

  • Valuation: unknown

  • Links: Company | Article

LambdaVision – US$ 7M (Seed) | Hartford, USA

  • What they do: Protein-based artificial retina manufactured in microgravity (ISS) to restore vision in RP/AMD.

  • Why it matters: A restorative implant for degenerative retinal disease could return core function for older adults, preventing the cascade of decline (falls, isolation, cognitive impact) that follows vision loss.

  • Investors: Co-led by Seven Seven Six an Aurelia Foundry Fund

  • Valuation: unknown

  • Links: Company | Article

Longevity Enablers (Category 3)

Hepta Bio – US$ 6.7M (Seed) | Foster City, USA

  • What they do: Liquid biopsy platform for chronic disease detection/monitoring (beyond oncology) via blood-based molecular signals.

  • Why it matters: Earlier, lower-friction detection across chronic conditions is the purest longevity enabler. It shifts care to prevention and course-correction before organ damage accumulates.

  • Investors: Led by Felicis Ventures and Illumina Ventures

  • Valuation: unknown

  • Links: Company | Article

Want the full weekly funding database? Subscribe for free!

📰 Top longevity business news

Arena Bioworks shuts down, claiming ‘biotech funding winter’

  • What happened:
    Arena Bioworks, a once-promising biotech collective that aimed to accelerate drug discovery across aging-related diseases, announced its closure, citing deteriorating macroeconomic conditions and reduced venture appetite for preclinical risk. Read more here.

  • Why it matters:
    This marks one of the first high-profile collapses (US$ 500M in funding from high-profile investors) of a platform biotech in the post-2021 funding reset. It underscores the contraction in early-stage capital for longevity-related therapeutics and highlights a shift from “moonshot biology” toward leaner, translational models. For investors, it signals an industry-wide reprioritisation toward capital efficiency and nearer-term clinical validation.

Don’t want to miss any exclusive analysis? Subscribe for free!

🗓 Events & meetups (Europe-only)

Share this article with others who might benefit.

Share

💼 New Longevity jobs (Europe-only)

👉 To see the full list of all Longevity jobs, visit our Job Board.

Keep building the future of longevity - one week at a time.
Fabian

P.S. Want your open positions or events to be featured? Just send them my way by replying to this email.

]]><![CDATA[Last Week in Longevity #13 - $193M raised + €2.5bn for healthcare investments ]]>https://longevitybuilders.eu/p/last-week-in-longevity-13-193m-raisedhttps://longevitybuilders.eu/p/last-week-in-longevity-13-193m-raisedTue, 04 Nov 2025 12:46:00 GMT👋 Hi, I am Fabian, and welcome to my newsletter Last Week in Longevity. Every week, I track where the money, talent, and ideas are moving in the longevity business.

💸 Closed funding rounds

US$ 193M raised across 5 deals (↘️ -19% vs. US$ 239M across 6 deals last week)


Direct Longevity Interventions (Category 1)

Blueprint (Bryan Johnson) – US$ 60M | Los Angeles, USA

  • What they do: “Project Blueprint” lifestyle & prevention protocol being productized as a consumer platform (nutrition, sleep, exercise, monitoring).

  • Why it matters: If successfully standardised and scaled, structured prevention could shift large populations toward earlier, measurable healthspan gains.

  • Investors: long list of celebrity investors incl. Kim Kardashian, Logan Paul, Steve Aoki and many more

  • Valuation: unknown

  • Links: Company | Article

Longevity-Aligned Disease Modification (Category 2)

Zag Bio – US$ 80M (Series A) | Cambridge, USA

  • What they do: Thymus-targeted bifunctional antibodies to induce central immune tolerance; lead in Type 1 diabetes.

  • Why it matters: Durable, antigen-specific tolerance could reduce lifelong autoimmune burden and complications that shorten healthspan.

  • Investors: co-led by Polaris and the T1D Fund; participants include Mission BioCapital, AbbVie Ventures, Lightspeed Ventures, Sanofi Ventures, KdT Ventures, Regeneron Ventures, Boxer Capital, Pear VC, among others

  • Valuation: unknown

  • Links: Company | Article

Adaptam Therapeutics – €3M (pre-seed) | Barcelona/San Sebastián, Spain

  • What they do: Cancer immunotherapies targeting immunosuppressive myeloid cells (incl. ADCs and bispecifics).

  • Why it matters: Better myeloid-targeted IO could improve outcomes and tolerability in age-associated cancers.

  • Investors: Led by Criteria Bio Ventures (founding investor)

  • Valuation: unknown

  • Links: Company | Article

Longevity Enablers (Category 3)

Curve Biosciences – US$ 40M (financing) | San Mateo, USA

  • What they do: “Whole-Body Intelligence” platform—tissue-anchored atlas + blood tests to anticipate and monitor chronic disease.

  • Why it matters: Earlier, system-level detection can personalize prevention/therapy and compress morbidity—classic Category 3 longevity enabler.

  • Investors: Led by Luma Group; participants include First Spark Ventures, Techas Capital, Civilization Ventures, LifeX Ventures, Incite, Mintaka VC, NZVC and others.

  • Valuation: unknown

  • Links: Company | Article

Bevel – US$ 10M (Series A) | New York, USA

  • What they do: AI health companion that unifies wearable and habit data (sleep, fitness, nutrition) into personalized daily guidance.

  • Why it matters: Continuous behavioral guidance and adherence support enable earlier course-corrections and measurable risk-reduction at population scale.

  • Investors: General Catalyst (Series A lead)

  • Valuation: unknown

  • Links: Company | Article

Want the full weekly funding database? Subscribe for free!

📰 Top longevity business news

€2.5 bn fund signals Europe’s healthcare-investment surge

  • What happened:
    GHO Capital closed its Fund IV at over €2.5 billion, bringing its total assets under management (AUM) to around €9 billion — making it Europe’s largest healthcare-specialist private equity firm. Read more here.

  • Why it matters:
    For the longevity & health-tech sector this is a strong signal: first, large pools of capital are available specifically for healthcare/biotech/medtech in Europe, which means more investment flows into longevity-adjacent businesses. Second, the sheer size of the fund suggests investor conviction in this sector despite broader macro uncertainty. Third, having such a major fund active in Europe improves the exit/opportunity environment for startups in longevity, meaning earlier-stage companies have more realistic paths to growth or acquisition.

Biotech VC rebounds 71% in Q3 2025 to US$3.1 billion

  • What happened:
    Venture capital investments in biotech rose ~70.9% in Q3 2025 (from US$1.8 billion in Q2 to US$3.1 billion), driven by later-stage rounds and M&A activity. Read more here.

  • Why it matters:
    From a longevity business perspective this is highly relevant: funding momentum is returning to biotech, which means more available capital and possibly better valuations for companies with credible longevity/health-span propositions. It also indicates a shift toward growth/later-stage rounds (Series D) rather than purely early-stage, which hints that investors are looking for more mature longevity propositions — meaning startups need stronger proof/pipeline to attract capital.

Don’t want to miss any exclusive analysis? Subscribe for free!

🗓 Events & meetups (Europe-only)

Share this article with others who might benefit.

Share

💼 New Longevity jobs (Europe-only)

👉 To see the full list of all Longevity jobs, visit our Job Board.

Keep building the future of longevity - one week at a time.
Fabian

P.S. Want your open positions or events to be featured? Just send them my way by replying to this email.

]]><![CDATA[Last Week in Longevity #12 - $239M raised + Ozempic slows aging by ~3.1 years ]]>https://longevitybuilders.eu/p/last-week-in-longevity-12-239m-raisedhttps://longevitybuilders.eu/p/last-week-in-longevity-12-239m-raisedTue, 28 Oct 2025 14:41:03 GMT👋 Hi, I am Fabian, and welcome to my newsletter Last Week in Longevity. Every week, I track where the money, talent, and ideas are moving in the longevity business.

💸 Closed funding rounds

US$ 239M raised across 6 deals (↘️ -78% vs. US$ 1,065M across 11 deals last week)


Direct Longevity Interventions (Category 1)

Knownwell – US$ 25M (growth round) | Boston, USA

  • What they do: Hybrid primary & metabolic care model combining obesity medicine, nutrition counselling, and health coaching through in-person clinics and virtual care.

  • Why it matters: Tackling obesity and metabolic dysfunction is one of the most effective levers to extend healthspan through clinically guided lifestyle change - a direct longevity intervention.

  • Investors: Led by CVS Health Ventures; joined by MassMutual Catalyst Fund, Intermountain Ventures, existing backers a16z Bio + Health and Flare Capital; Oak Street Health cofounder Geoff Price also invested.

  • Valuation: unknown

  • Links: Company | Article

Longevity-Aligned Disease Modification (Category 2)

Elevara Medicines – US$ 70M (Series A) | London, UK

  • What they do: Develops fibroblast-targeting small molecules for rheumatoid arthritis; non-immunosuppressive mechanism designed to complement biologics.

  • Why it matters: Chronic inflammation accelerates aging. A safer, more effective anti-inflammatory approach could maintain joint and immune health deep into later life.

  • Investors: Co-led by Forbion and Sofinnova Partners; joined by Monograph Capital and Weatherden.

  • Valuation: unknown

  • Links: Company | Article

Faeth Therapeutics – US$ 25M | San Francisco, USA

  • What they do: Cancer metabolism company using dietary and metabolic modulation to improve treatment response; advancing Phase 2 trials in endometrial and ovarian cancers.

  • Why it matters : Cancer is a central age-related disease. Metabolic interventions could improve therapy outcomes and tolerance, supporting a longer healthy lifespan.

  • Investors: Reported lead S2G Ventures; participation from prior backers Khosla Ventures, Future Ventures, and Digitalis Ventures.

  • Valuation: unknown

  • Links: Company | Article

Mission Therapeutics – US$ 13.3M | Cambridge, UK

  • What they do: Develops mitophagy-enhancing therapies via USP30 inhibition (MTX325) for Parkinson’s disease; advancing to proof-of-mechanism study.

  • Why it matters: Preserving mitochondrial quality directly supports cellular health and neuroprotection, delaying decline in aging brains.

  • Investors: Existing syndicate including Pfizer Ventures, Sofinnova Partners, Roche Venture Fund, SR One, IP Group, and Rosetta Capital; supported by MJFF and Parkinson’s UK.

  • Valuation: unknown

  • Links: Company | Article

Longevity Enablers (Category 3)

Generation Lab – US$ 11M (Seed) | San Francisco, USA

  • What they do: Develops “SystemAge,” a blood test analysing 460 biomarkers to quantify organ-specific aging and identify personalised health risks.

  • Why it matters: Enables individuals and clinicians to monitor biological aging early and intervene proactively — a key step for measurable prevention.

  • Investors: Led by Accel (its first longevity investment); joined by Samsung Next and angels including Steve Aoki (Aoki Labs), Giannis Antetokounmpo (BYL Ventures), and Simu Liu (Markham Valley Ventures).

  • Valuation: unknown

  • Links: Company | Article

Longevity Ecosystem (Category 4)

Lanserhof Group – €95M (growth capital) | Munich, Germany

  • What they do: Operates high-end longevity and regenerative health resorts that combine preventive medicine, diagnostics, and wellness programs in medical spa environments.

  • Why it matters: Lanserhof is one of the most established brands bridging luxury wellness and evidence-based longevity care. The new capital fuels international expansion, signalling growing demand for preventive and lifestyle-focused longevity destinations.

  • Investors: Joint investment by AltamarCAM Partners and King Street Capital Management.

  • Valuation: unknown

  • Links: Company | Article

Want the full weekly funding database? Subscribe for free!

📰 Top longevity business news

Ozempic (semaglutide) shows potential to reverse biological age in first human trial

  • What happened:
    A 32-week, double-blind, placebo-controlled trial found that semaglutide (the active ingredient in Ozempic) reduced participants’ biological age by ~3.1 years on average and slowed the pace of aging by roughly 9%. Read more here.

  • Why it matters:
    This is among the first human data linking a widely used metabolic drug to measurable changes in epigenetic ageing clocks—markers tied to multiple organ systems (brain, heart, kidney) and inflammation. The implications are significant: a drug already approved for diabetes/obesity may be repurposed (or spur repurposing) into the longevity/health-span domain. For longevity businesses, this opens up new pathways, from diagnostics (biological age tests) to combination therapies. However: the trial was in a specific population (HIV patients) and broader generalisability remains to be proven, so caution is needed before over-claiming commercial potential.

Don’t want to miss any exclusive analysis? Subscribe for free!

🗓 Events & meetups (Europe-only)

Share this article with others who might benefit.

Share

💼 New Longevity jobs (Europe-only)

👉 To see the full list of all Longevity jobs, visit our Job Board.

Keep building the future of longevity - one week at a time.
Fabian

P.S. Want your open positions or events to be featured? Just send them my way by replying to this email.

]]><![CDATA[Last Week in Longevity #11 - $1B raised across 11 deals ]]>https://longevitybuilders.eu/p/last-week-in-longevity-11-1b-raisedhttps://longevitybuilders.eu/p/last-week-in-longevity-11-1b-raisedTue, 21 Oct 2025 16:16:16 GMT👋 Hi, I am Fabian, and welcome to my newsletter Last Week in Longevity. Every week, I track where the money, talent, and ideas are moving in the longevity business.

💸 Closed funding rounds

US$ 1,065M raised across 11 deals (↗️ +18% vs. US$ 899M across 6 deals last week)


Direct Longevity Interventions (Category 1)

NewLimit – US$ 45M (strategic extension) | San Francisco, USA

  • What they do: Develop epigenetic reprogramming therapies to return aged cells to more youthful states and restore organ function (company highlights liver as a target tissue).

  • Why it matters: Reprogramming is mechanistically upstream of age-related diseases; successful restoration of youthful gene-expression programs could extend healthspan independent of a single disease label. Their recent communications emphasise plans toward clinical translation in liver, a tractable first indication to demonstrate rejuvenation in humans.

  • Investors: New round features Lilly Ventures, Duke University, Section 32 (S32), among others.

  • Valuation: $1.62B

  • Links: Company | Article

Simple Life – US$ 35 M (Series A) | San Francisco, USA

  • What they do: AI-powered behaviour-change platform combining nutritional coaching, metabolic tracking & community engagement for sustainable weight loss.

  • Why it matters: Metabolic dysfunction is an upstream driver of ageing. Precision lifestyle modification remains one of the most validated longevity levers.

  • Investors: Accel (lead), Index Ventures, Samsung Next, Greycroft and others.

  • Valuation: Unknown

  • Links: Company | Article

WellTheory – US$ 14 M (Series A) | New York, USA

  • What they do: Virtual care platform for autoimmune management through personalised nutrition and lifestyle medicine.

  • Why it matters: Targets chronic inflammation — a key biological hallmark of ageing — via structured prevention and clinically guided habit change.

  • Investors: General Catalyst (lead), Accretive, Lux Capital.

  • Valuation: Unknown

  • Links: Company | Article

Longevity-Aligned Disease Modification (Category 2)

Liberate Bio – US$ 31 M (Seed) | Cambridge, USA

  • What they do: In vivo genetic medicines reprogram immune cells using mRNA & LNPs to treat autoimmunity and cancer.

  • Why it matters: Rejuvenates immune resilience by correcting dysfunction at a root cause of ageing.

  • Investors: Khosla Ventures.

  • Valuation: Unknown

  • Links: Company | Article

Pelage Pharmaceuticals – US$ 120 M (Series B) | Los Angeles, USA

  • What they do: Reactivates dormant hair-follicle stem cells to reverse hair loss.

  • Why it matters: Demonstrates functional stem-cell rejuvenation — a central anti-ageing mechanism.

  • Investors: ARCH Venture Partners, GV, Visionary Ventures, Main Street Advisors, YK Bioventures.

  • Valuation: Unknown

  • Links: Company | Article

Kardigan – US$ 254 M (Series B) | San Francisco & Princeton, USA

  • What they do: Late-stage portfolio of personalised cardiovascular medicines targeting root causes of heart disease.

  • Why it matters: Cardiovascular repair directly extends lifespan and healthspan by slowing vascular ageing.

  • Investors: Fidelity Management, T. Rowe Price, ARCH Venture Partners, Sequoia Heritage.

  • Valuation: Unknown

  • Links: Company | Article

Adcytherix – €105 M (≈ US$ 114 M, Series B) | Marseille, France

  • What they do: Develops novel antibody-drug conjugates (ADCs) for solid tumours with reduced toxicity.

  • Why it matters: Safer, more precise cancer therapeutics enhance survivorship and life expectancy.

  • Investors: Bpifrance, Sofinnova Partners, Andera Partners, Kurma Partners.

  • Valuation: Unknown

  • Links: Company | Article

Nova Pulse Therapeutics – Undisclosed (Series A) | New York, USA

  • What they do: Uses focused ultrasound to destroy tumours and stimulate immune response.

  • Why it matters: Offers a non-toxic, regenerative oncology approach — a major step toward longevity-compatible cancer care.

  • Investors: Founders Fund (Peter Thiel), Bezos Expeditions, ARCH Venture Partners.

  • Valuation: Unknown

  • Links: Company | Article

Tubulis – US$ 335 M, Series C | Munich, Germany

  • What they do: Next-gen ADC platform with proprietary linker chemistry for more precise, less toxic cancer drugs.

  • Why it matters: Improves efficacy and safety in oncology—boosting healthy longevity through durable, low-toxicity remission.

  • Investors: EQT Life Sciences, Andera Partners, Mubadala Capital, Fund+, BioMedPartners, Roche Venture Fund.

  • Valuation: Unknown

  • Links: Company | Article

Longevity Enablers (Category 3)

CoMind – US$ 102.5 M (Series B) | London, UK

  • What they do: Non-invasive AI platform for continuous brain-activity and blood-flow monitoring.

  • Why it matters: Enables early detection of cognitive decline and neurodegeneration—shifting brain health from reactive care to prevention.

  • Investors: Andreessen Horowitz, General Catalyst, Mubadala Capital, others.

  • Valuation: Unknown

  • Links: Company | Article

Adaptyx Biosciences – US$ 14 M (Seed) | Menlo Park, USA

  • What they do: Multi-analyte biowearable for continuous molecular monitoring using AI analytics.

  • Why it matters: Real-time detection of metabolic drift and inflammation allows truly preventive medicine.

  • Investors: Interlagos Ventures (lead), Overwater Ventures, Starbloom Capital, CZ Biohub, Cantos Ventures, and others.

  • Valuation: Unknown

  • Links: Company | Article

Want the full weekly funding database? Subscribe for free!

📰 Top longevity business news

The CEO of General Catalyst says that longevity care should be reimbursable

  • What happened:
    Hemant Taneja, CEO of the venture firm General Catalyst, in a podcast, argued that longevity and personal health interventions should be reimbursed by health-insurers, rather than treated as premium wellness add-ons. Read more here.

  • Why it matters:
    Of course, I agree! This would mark an important strategic shift in how longevity could integrate into mainstream healthcare economics. If reimbursement frameworks evolve to value healthspan extension alongside disease treatment, the longevity market could grow far beyond wealthy consumers, tapping insurer budgets and institutional payers. But realising this will require proof of ROI and policy alignment, making clinical validation and outcomes data the next competitive frontier for longevity companies.

Don’t want to miss any exclusive analysis? Subscribe for free!

🗓 Events & meetups (Europe-only)

Share this article with others who might benefit.

Share

💼 New Longevity jobs (Europe-only)

👉 To see the full list of all Longevity jobs, visit our Job Board.

Keep building the future of longevity - one week at a time.
Fabian

P.S. Want your open positions or events to be featured? Just send them my way by replying to this email.

]]><![CDATA[Last Week in Longevity #10 - $899M raised + Singapore goes longevity]]>https://longevitybuilders.eu/p/last-week-in-longevity-10-899m-raisedhttps://longevitybuilders.eu/p/last-week-in-longevity-10-899m-raisedWed, 15 Oct 2025 15:30:26 GMT👋 Hi, I am Fabian, and welcome to my newsletter Last Week in Longevity. Every week, I track where the money, talent, and ideas are moving in the longevity business.

💸 Closed funding rounds

US$ 899M raised across 6 deals (↗️ +41% vs. US$ 637M across 4 deals last week)


Kailera Therapeutics – US$600M (Series B) | Waltham, USA

  • Category: 2 - Longevity-aligned disease modification

  • What they do: Late-stage GLP-1/GIP injectable (KAI-9531) and oral GLP-1 program for obesity.

  • Why it matters: We all know: GLP-1s are currently being framed as the first real longevity drug, even though regulation isn’t there yet.

  • Investors: Bain Capital (led; PE unit)

  • Valuation: Unknown

  • Links: Company | Article

Expedition Therapeutics – US$165M (Series A) | San Francisco, USA

  • Category: 2 - Longevity-aligned disease modification

  • What they do: Next-gen DPP1 inhibitor (EXPD-101) for COPD and other neutrophil-driven diseases; gearing up for Phase 2.

  • Why it matters: COPD is a top 5 global killer, strongly age-skewed; oral DPP1 with better profile could reduce exacerbations and disability in older adults.

  • Investors: Co-led by Sofinnova Investments & Novo Holdings; joined by Forbion, KKR’s Dawn Biopharma, Adage, Balyasny, Logos Capital, Sanofi Ventures, existing BVF Partners, Venrock HCP.

  • Valuation: Unknown.

  • Links: Company | Article

NanoPhoria Bioscience – €83.5M (Series A) | Milan, Italy

  • Category: 2 - Longevity-aligned disease modification

  • What they do: Peptide NP-MP1 delivered via nano-in-micro lung-to-heart system to improve contractility in HFrEF.

  • Why it matters: Heart failure prevalence and mortality explode with age; platform that restores contractility (vs only slowing decline) could extend healthy cardiac function.

  • Investors: XGEN Venture (lead), Sofinnova Partners, CDP Venture Capital, Panakès Partners.

  • Valuation: Unknown.

  • Links: Company | Article

Affinia Therapeutics – US$40M (Series C) | Waltham, USA

  • Category: 2 - Longevity-aligned disease modification

  • What they do: AAV gene therapies; lead AFTX-201 for BAG3 dilated cardiomyopathy.

  • Why it matters: Cardiovascular failure is a prime limiter of healthspan. A one-time gene therapy restoring BAG3 and cardiac function, if it translates clinically, could materially extend functional lifespan in affected adults.

  • Investors: Led by NEA; Eli Lilly (new); existing Alexandria Venture Investments, Atlas Venture, Avidity Partners, F-Prime, GV, Mass General Brigham Ventures, Perceptive.

  • Valuation: Unknown

  • Links: Company | Article

Kneu Health – US$5.6M (Seed) | London & Oxford, UK

  • Category: 3 - Longevity enablers

  • What they do: Smartphone-based digital biomarkers (voice, motor, cognition) to detect/track neurodegeneration; FDA-cleared tech, large Parkinson’s/dementia dataset.

  • Why it matters: Continuous, low-friction monitoring enables earlier detection & intervention across Parkinson’s/dementia—key levers for preserving healthspan.

  • Investors: Oxford Science Enterprises & Cedars-Sinai (co-leads), Social Impact Enterprises, JIMCO, GK Goh Ventures, SXSW London.

  • Valuation: Unknown.

  • Links: Company | Article

Kihealth – US$5M (Seed) | St. Augustine, USA

  • Category: 3 - Longevity enablers

  • What they do: β-cell apoptosis liquid-biopsy diagnostic to catch diabetes earlier and guide therapy.

  • Why it matters: Diabetes risk explodes with age; a true pre-symptomatic marker could bend metabolic trajectories and reduce multi-organ aging burden.

  • Investors: Not disclosed

  • Valuation: Unknown

  • Links: Company | Article

Want the full weekly funding database? Subscribe for free!

📰 Top longevity business news

Singapore launches new national trial center for healthy longevity

  • What happened:
    The Singapore government announced the creation of a Healthy Longevity Translational Research Center, focused on testing and validating longevity interventions in clinical settings. Read more here.

  • Why it matters:
    This is a geopolitical milestone: few countries have established state-backed longevity infrastructure with such a clear focus on clinical trials rather than academic research alone. It could make Singapore one of the most important global hubs for longevity medicine, similar to what Basel is for pharma.
    Such centralized clinical infrastructure can de-risk early-stage companies and accelerate regulatory acceptance of aging-targeted interventions.

Partnership to launch peptide therapeutics for women’s health

  • What happened: Telehealth platform Wisp and Vesalius Longevity Labs announced a partnership to develop peptide-based therapeutics aimed at women’s health and aging, with a focus on hormonal health, metabolic resilience, and perimenopause. Read more here.

  • Why it matters: Women are currently underrepresented in longevity trials and biotech innovation — this is one of the first peptide-centric longevity partnerships targeting women’s health specifically. Peptides represent a fast-moving, lower regulatory barrier segment with real consumer demand (HGH mimetics, metabolic peptides). This move could accelerate mainstream adoption of longevity therapeutics in consumer telehealth channels, a trend similar to the GLP-1 explosion but focused on hormonal and metabolic aging in women.

Strava eyes IPO as Gen Z ditches dating apps for running clubs

  • What happened: Strava, the fitness-tracking and social running app, is preparing for a public listing, leveraging surging adoption by younger users and doubling its user base to ~50 million monthly active users. Read more here.

  • Why it matters: It signals the monetisation maturation of consumer health & fitness apps. Strava claims over $180 million in subscription revenue. A successful IPO would attract large institutional capital into consumer wellness/behaviour change ecosystems, accelerating consolidation and possibly fueling M&A in adjacent longevity domains (wearables, health coaching, digital therapeutics).

Don’t want to miss any exclusive analysis? Subscribe for free!

🗓 Events & meetups (Europe-only)

Share this article with others who might benefit.

Share

💼 New Longevity jobs (Europe-only)

👉 To see the full list of all Longevity jobs, visit our Job Board.

Keep building the future of longevity - one week at a time.
Fabian

P.S. Want your open positions or events to be featured? Just send them my way by replying to this email.

]]><![CDATA[Last Week in Longevity #9 - $637M raised + FDA reverses NMN decision]]>https://longevitybuilders.eu/p/last-week-in-longevity-9-637m-raisedhttps://longevitybuilders.eu/p/last-week-in-longevity-9-637m-raisedTue, 07 Oct 2025 17:59:50 GMT👋 Hi, I am Fabian, and welcome to my newsletter Last Week in Longevity. Every week, I track where the money, talent, and ideas are moving in the longevity business.

💸 Closed funding rounds

US$ 637M raised across 4 deals (↗️ +426% vs. US$ 121M across 4 deals last week)


Algen Biotechnologies – US$ 555M (strategic partnership) | San Francisco, USA

  • What they do: Combines CRISPR-based gene modulation with AI to map how gene activity causes disease, identifying targets with strong human translational relevance.

  • Why it matters: By distinguishing genes that drive rather than correlate with disease, Algen’s approach could reveal mechanisms behind complex, age-related disorders like neurodegeneration and chronic inflammation, accelerating therapies that slow or reverse biological aging in the future.

  • Investors / Partners: Strategic R&D partnership with AstraZeneca valued at up to $555M in upfront, near-term, and milestone payments (no equity investment).

  • Valuation: undisclosed

  • Links: Company | Article

Midi Health – US$ 50M (Series C) | Palo Alto, USA

  • What they do: Provides virtual care for perimenopause, menopause, and midlife women’s health, combining hormonal and non-hormonal treatments with diagnostics, coaching, and supplements. Recently launched AgeWell, a preventive longevity program targeting cardiovascular, brain, and bone health.

  • Why it matters: Menopause accelerates aging via hormonal shifts affecting metabolism, cognition, and inflammation. Midi’s data-driven, AI-supported approach reframes midlife women’s care as proactive longevity medicine, closing a gender gap in the field.

  • Investors: Led by Advance Venture Partners; earlier investors include Emerson Collective, GV (Google Ventures), and angels, including Anne Wojcicki.

  • Valuation: undisclosed

  • Links: Company | Article

Aerska – US$ 21M (Seed) | Dublin, Ireland

  • What they do: Develops RNA interference (RNAi) medicines capable of crossing the blood–brain barrier to silence disease-driving genes in neurodegenerative disorders like Alzheimer’s and Parkinson’s. Uses receptor-mediated “brain shuttle” technology for precise, repeatable delivery to neurons.

  • Why it matters: Neurodegeneration is a key limiter of healthspan. Aerska’s ability to deliver gene-silencing RNAi to the brain could enable preventive interventions that delay or stop cognitive decline in genetically at-risk populations.

  • Investors: Co-led by Age1, Backed VC, and Speedinvest; joined by Blueyard, Lingotto, Norrsken VC, Kerna, PsyMed, and Ada Ventures.

  • Valuation: undisclosed

  • Links: Company | Article

Cirrus Therapeutics – US$ 11M (Seed) | Cambridge, USA

  • What they do: Develops gene therapies to rejuvenate the retina by restoring levels of IRAK-M, a protein that declines with age and regulates immune balance in the eye.

  • Why it matters: Cirrus directly targets two of aging’s core mechanisms, immune dysregulation and mitochondrial decline, in order to reverse biological aging in retinal cells. Its approach could preserve vision and independence deep into old age, extending functional healthspan.

  • Investors: Led by ClavystBio, with participation from Polaris Partners and SEEDS.

  • Valuation: undisclosed

  • Links: Company | Article

Want the full weekly funding database? Subscribe for free!

📰 Top longevity business news

FDA reverses NMN decision

  • What happened: After years of regulatory back-and-forth, the FDA reversed its prior position and ruled that NMN (nicotinamide mononucleotide) is not excluded from being sold as a dietary supplement. Read more here.

  • Why it matters: This regulatory pivot reopens a major consumer supplement market for NMN, easing pressures on firms to push it through drug channels. It might also set a precedent for how other compounds straddling the supplement/drug line could be handled, and it is a reminder that we need clear regulatory guidelines for substances with both supplement and pharmaceutical potential.

Investing in the future of longevity

  • What happened: At the Longevity Investors Conference (LIC) 2025 in Gstaad, investors, scientists, and founders convened to debate how AI, equity, and collaboration can push longevity innovation toward translation and scale. The tone shifted: less hype, more “what can we build now,” with special emphasis on inclusion and women’s healthspan. Read more here.

  • Why it matters: The shift toward pragmatic investment and equitable access signals maturation in the longevity ecosystem. Those who can deliver near-term utility rather than speculative bets will gain trust and capital.

Don’t want to miss any exclusive analysis? Subscribe for free!

🗓 Events & meetups (Europe-only)

Share this article with others who might benefit.

Share

💼 New Longevity jobs (Europe-only)

👉 To see the full list of all Longevity jobs, visit our Job Board.

Keep building the future of longevity - one week at a time.
Fabian

P.S. Want your open positions or events to be featured? Just send them my way by replying to this email.

]]><![CDATA[Last Week in Longevity #8 - $121M raised + Biostasis goes (more) mainstream]]>https://longevitybuilders.eu/p/last-week-in-longevity-8-121m-raisedhttps://longevitybuilders.eu/p/last-week-in-longevity-8-121m-raisedTue, 30 Sep 2025 07:11:23 GMT👋 Hi, I am Fabian, and welcome to my newsletter Last Week in Longevity. Every week, I track where the money, talent, and ideas are moving in the longevity business.

💸 Closed funding rounds

US$ 121M raised across 4 deals (↘️ -88% vs. US$ 1,002M across 6 deals last week)


Until Labs – US$ 58M (Series A) | San Francisco, USA

  • What they do: Developing organ cryopreservation technology for transplantation, pausing biological time to extend the viable window for donated organs.

  • Why it matters: Extending organ viability not only saves transplant patients but also lays the groundwork for broader biostasis applications.

  • Investors: Led by Founders Fund, with Lux and Field Ventures joining in

  • Valuation: unknown

  • Links: Company | Article

Sunrise Group (Dreem Health) – US$ 29M (Series A) | Paris, France & New York, USA

  • What they do: Expanding Dreem Health, a network of sleep clinics augmented by digital sleep tracking, to become the largest US provider of sleep diagnostics and therapy.

  • Why it matters: Poor sleep accelerates nearly every hallmark of aging (inflammation, mitochondrial dysfunction etc.). Scaling modern sleep clinics puts one of the most powerful levers of healthspan into mainstream care.

  • Investors: Led by Eurazeo, with participation from Amazon’s Alexa Fund, WE International, Kurma Partners, Vives Fund, Majycc and others

  • Valuation: unknown

  • Links: Company | Article

Manas AI – US$ 26M (Seed Extension) | New York, USA

  • What they do: Building a generalist biomedical AI agent that integrates omics, imaging, and literature to propose new drug targets and therapeutic hypotheses.

  • Why it matters: Longevity medicine is multi-modal and complex; an AI engine able to synthesise biology at scale could accelerate target discovery for hallmarks like senescence, mitochondrial dysfunction, or proteostasis loss.

  • Investors: The General Partnership, Wisdom Ventures, Blitzscaling Ventures, Westbound Equity Partners, Mosaic Ventures

  • Valuation: unknown

  • Links: Company | Article

FYR Bio – US$ 8M (Seed/early funding) | Missoula, USA

  • What they do: Using advanced neuroproteomics and biomarker discovery to identify early warning signals for Parkinson’s disease and expand to other neurodegenerative conditions.

  • Why it matters: Neurodegeneration is one of the largest barriers to healthy aging. Earlier, blood-based biomarkers could enable pre-symptomatic intervention, shifting from late-stage management to prevention.

  • Investors: The Sonntag Innovation Fund and Yuvaan Tiwari Foundation

  • Valuation: unknown

  • Links: Company | Article

Want the full weekly funding database? Subscribe for free!

📰 Top longevity business news

GLP-1 + X = IP moats & better outcomes?

  • What happened: Austin-based MindWalk announced an AI-designed GLP-1 analog paired with a companion therapeutic acting via a complementary “healthy-aging” pathway, framing a dual-pathway regimen for healthspan. Read more here.

  • Why it matters: We have seen Eli Lilly and Novo Nordisk framing GLP-1s as the first longevity drug. MindWalk is going down the same path, saying that biomarkers of aging and healthspan endpoints are being incorporated into the preclinical prioritisation process. Also, combo regimens could create IP moats and better outcomes, positioning MindWalk in the high-margin “GLP-1 + X” stack many pharma players are chasing.

L-Nutra × Parsley Health partnership

  • What happened: L-Nutra partnered with Parsley Health to embed fasting-mimicking protocols and products into Parsley’s physician-led metabolic programs, training care teams and selling via its store. Read more here.

  • Why it matters: This shifts longevity nutrition from DTC into clinical workflows, improving adherence, medical legitimacy, and unit economics through platform distribution.

Don’t want to miss any exclusive analysis? Subscribe for free!

🗓 Events & meetups (Europe-only)

Share this article with others who might benefit.

Share

💼 Longevity jobs (Europe-only)

Germany:

Rest of Europe:

Keep building the future of longevity - one week at a time.
Fabian

P.S. Want your open positions or events to be featured? Just send them my way by replying to this email.

]]><![CDATA[Last Week in Longevity #7 - $1B (!!) raised + Whoop: blood tests need context]]>https://longevitybuilders.eu/p/last-week-in-longevity-7-1b-raisedhttps://longevitybuilders.eu/p/last-week-in-longevity-7-1b-raisedTue, 23 Sep 2025 14:51:43 GMT👋 Hi, I am Fabian, and welcome to my newsletter Last Week in Longevity. Every week, I track where the money, talent, and ideas are moving in the longevity business.

💸 Closed funding rounds

US$ 1,002M raised across 6 deals (↗️ +221% vs. US$ 312M across 6 deals last week)


Oura Health – US$ 875M (Series E) | Oulu, Finland

  • What they do: Maker of the Oura Ring, a consumer health wearable that tracks sleep, activity, and recovery with advanced biometrics.

  • Why it matters: The $11B valuation cements Oura as one of the most valuable health hardware companies, proving consumer demand for continuous health tracking, a key longevity enabler.

  • Investors: (undisclosed)

  • Valuation: ~US$ 11B

  • Links: Company | Article

Ensoma – US$ 53M (Series B extension) | Boston, USA

  • What they do: Develops non-viral gene therapies, including EN-374 for hemophilia.

  • Why it matters: Non-viral delivery systems enhance the safety and scalability of gene therapies, with potential applications in age-related diseases such as cardiovascular disease.

  • Investors: Gilead, the Gates Foundation, Hanwha Impact Partners, Mirae Asset Financial Group, Qatar Investment Authority (QIA), RTW, and more

  • Valuation: (unknown)

  • Links: Company | Article

AllRock Bio – US$ 50M (Series A) | Shanghai, China

  • What they do: Developing novel therapies for pulmonary hypertension (PH) using a pan-ROCK inhibitor approach.

  • Why it matters: ROCK activity tends to be upregulated with aging, contributing to vascular stiffening, chronic inflammation, and tissue fibrosis. Pan-ROCK inhibitors could therefore be interesting as anti-fibrotic and vascular-protective longevity drugs.

  • Investors: Versant Ventures and Westlake BioPartners

  • Valuation: (unknown)

  • Links: Company | Article

Nutrium – US$ 12M (Series A) | Braga, Portugal

  • What they do: combining a software platform that helps dietitians manage their workstreams, with a corporate wellness program that brings personalised nutrition to workplaces and their employees.

  • Why it matters: Nutrium makes personalized dietary care scalable.

  • Investors: Vesalius Biocapital, MAZE, Lince Capital, Indico Capital Partners, and Beta Capital

  • Valuation: (unknown)

  • Links: Company | Article

Bio-Protocol – US$ 6.9M (Seed) | Global

  • What they do: decentralised science (DeSci) platform enabling researchers and patients to launch BioAgents - autonomous AI co-scientists that generate hypotheses, fund experiments, and monetise biotech discoveries.

  • Why it matters: Combines AI and blockchain to democratize access to drug discovery resources, including aging research. The first agent, Aubrai, launched in August in partnership with VitaDAO and renowned longevity researcher Aubrey de Grey.

  • Investors: Animoca Brands, Maelstrom, and more

  • Valuation: (unknown)

  • Links: Company | Article | Last Week in Longevity #3

Nutromics – US$ 5M (Bridge round) | Melbourne, Australia

  • What they do: Developing “lab-on-a-patch” continuous biomarker monitoring technology beyond glucose, including lactate and Vancomycin.

  • Why it matters: Could enable real-time tracking of aging-relevant biomarkers like inflammation proteins, metabolic markers, and cardiac stress signals, shifting diagnostics from episodic blood draws to real-time monitoring.

  • Investors: (unknown)

  • Valuation: (unknown)

  • Links: Company | Article

Want the full weekly funding database? Subscribe for free!

📰 Top longevity business news

Whoop brings health and performance context to blood tests

  • What happened: Whoop is partnering with Quest Diagnostics to launch Whoop Advanced Labs, allowing members to order and track clinical blood tests directly in the app. The service will cover biomarkers for metabolism, hormones, inflammation, cardiovascular health, and nutrient status. Read more here.

  • Why it matters: Standalone blood panel startups are in a tough position: Prices are falling, blood draws are standardised, and the underlying lab work is a commodity. In this environment, differentiation doesn’t come from the test itself but from the ecosystem built around it. That is why Whoop’s move is so interesting. With years of individualised health and performance data, it has the raw material to turn simple blood panels into a far richer, more personalised health experience. The real question is execution: Can Whoop connect daily sensor data with episodic blood tests in a way that produces insights people will actually act on?

Ultrahuman turns profitable, revenue soars 5x in FY25

  • What happened: India-based wearable startup Ultrahuman reported USD 58M in operating revenue in FY25 (5.4x growth YoY) and its first profit of USD 8M. Read more here.

  • Why it matters: Smart Ring War, Oura’s massive funding round and now Ultrahuman turning a profit - the smart ring/wearable category is on fire! Ultrahuman sets a benchmark for other wearable/health-monitoring startups and could shift investor expectations: product + service mix, margin structure, and path to meaningful revenue are no longer theoretical but demonstrable.


Next Ventures closes $60M Fund II investing in longevity

  • What happened: Next Ventures announced the close of its second fund at $60 million. The firm is investing in “whole-person health” startups that empower individuals to take ownership of their well-being, extend their longevity, and define the future of health. Read more here.

  • Why it matters: This reframes longevity from a narrow focus on biotech to a broader consumer health movement, where diagnostics, fitness, nutrition, and AI all intersect. Next Ventures is betting that the future of longevity will be built on consumer-facing, scalable businesses that embed healthspan into everyday culture, not just experimental science.

Don’t want to miss any exclusive analysis? Subscribe for free!

🗓 Events & meetups (Europe-only)

Share this article with others who might benefit.

Share

💼 Longevity jobs (Europe-only)

Germany:

Rest of Europe:

Keep building the future of longevity - one week at a time.
Fabian

P.S. Want your open positions or events to be featured? Just send them my way by replying to this email.

]]><![CDATA[Last Week in Longevity #6 - $ 312M raised + the 1st blockbuster longevity drug]]>https://longevitybuilders.eu/p/last-week-in-longevity-6-312m-raisedhttps://longevitybuilders.eu/p/last-week-in-longevity-6-312m-raisedTue, 16 Sep 2025 10:03:44 GMT👋 Hi, I am Fabian, and welcome to my newsletter Last Week in Longevity. Every week, I track where the money, talent, and ideas are moving in the longevity business.

💸 Closed funding rounds

US$ 312M raised across 6 deals (↗️ +61% vs. US$ 194M across 8 deals last week)

Odyssey Therapeutics – US$ 213M (Series D) | Boston, USA

  • What they do: Builds precision small-molecule therapies for autoimmune and inflammatory diseases, advancing multiple clinical and preclinical programs.

  • Why it matters: A high-capitalised, late-stage attempt to target the “chronic inflammation” hallmark of aging safely and durably.

  • Investors: Dimension Capital, Jeito Capital, Lightspeed, TPG Life Sciences, Wedbush, Affinity Asset Advisors, and existing investors

  • Valuation: (unknown)

  • Links: Company | Article


Diana Health – US$ 55M (Series C) | New York, USA

  • What they do: Builds modern women’s health clinics integrated with hospitals, offering services across gynecology, maternity care, menopause care, as well as annual checkups, mental health and nutrition and wellness coaching.

  • Why it matters: Diana Health tackles a structural blind spot: women’s health across the lifespan.

  • Investors: Norwest Venture Partners (lead), .406 Ventures, LRVHealth, AlleyCorp

  • Valuation: (unknown)

  • Links: Company | Article


Alchemab Therapeutics – US$ 32M (Series A extension) | Cambridge, UK

  • What they do: Their platform uses AI and large patient-derived antibody databases to identify naturally occurring protective auto-antibodies from people who are resilient to disease. They just started human trials with their first antibody candidate.

  • Why it matters: Alchemab is a longevity company in disguise. It’s positioned as an antibody biotech, but the core thesis (understand why some people age healthily and bottle it as medicine) is exactly what the longevity field needs.

  • Investors: Ono Venture Investment, RA Capital, SV Health Investors, DCVC Bio, Lightstone Ventures; strategic investment from Eli Lilly

  • Valuation: (unknown)

  • Links: Company | Article


Cellvie – US$ 5M (Seed/Extension) | Zurich, Switzerland

  • What they do: Pioneering mitochondria transplantation therapy: delivering functional mitochondria into patients’ cells to restore energy production, initially for organ transplants and ischemia-related injuries.

  • Why it matters: Mitochondrial dysfunction drives both acute and age-related diseases. Therapeutic transplantation could become a whole new treatment category.

  • Investors: Taiho Ventures, Kizoo Technology Capital and Beiersdorf Venture Capital

  • Valuation: (unknown)

  • Links: Company | Article


Meela – US$ 3.5M (Seed) | New York, USA

  • What they do: Launched a personalised AI voice companion for seniors that combats loneliness and social isolation through scheduled phone calls.

  • Why it matters: Loneliness is a major risk factor for morbidity and early mortality in older adults, with impacts comparable to smoking. Meela scales companionship and early detection of health concerns without requiring new devices, potentially enhancing both emotional well-being and preventive care in aging populations.

  • Investors: Bain Capital Ventures (BCV)

  • Valuation: (unknown)

  • Links: Company | Article


OpenHealth – US$ 3M (Seed) | Berlin, Germany

  • What they do: Centralise, harmonise and interpret fragmented medical lab results using AI, helping clinicians and patients understand health data more clearly and make it actionable.

  • Why it matters: A core bottleneck in longevity adoption is “actionable biomarker feedback.” Could plug into longevity clinics, digital health platforms, or insurers focused on prevention.

  • Investors: Ascension Ventures, Oxford Technology Management, angel syndicates

  • Valuation: (unknown)

  • Links: Company | Article

Want the full weekly funding database? Subscribe for free!

📰 Top longevity business news

GLP-1s: The world's first longevity drug?

  • What happened: At ARDD2025 in Copenhagen, Eli Lilly and Novo Nordisk framed GLP-1s not only as treatments for diabetes or obesity, but as the first true longevity drugs. Read more here.

  • Why it matters: Big pharma has historically shied away from making aging a viable drug development target - too broad, too complex, too hard to measure. Rebranding GLP-1s as longevity drugs could signal a turning point, shifting longevity from a niche research sector to a core pillar of pharmaceutical strategy. It also underscores the commercial reality that longevity drugs have blockbuster potential.


Vodka brand opens athletic club

  • What happened: ”For years, Cîroc has been synonymous with nightlife. But nightlife alone doesn’t capture where culture is heading. Luxury today is broader, more intentional, and rooted in how people connect. That’s why we’ve launched The Cîroc Athletic Club.” Read more here.

  • Why it matters: What sounds like an April Fools’ joke at first glance shows how even luxury alcohol players see “wellness” and “active living” as the future of aspirational branding. Longevity is not just about biotech or supplements, it is a cultural movement reshaping consumer behavior.

Can Special Economic Zones (SEZ) accelerate the launch of longevity therapies ?

  • What happened: Unlimited Bio thinks so. They are operating in the special economic zone of Prospera in Honduras, and are offering gene therapies aimed at tissue rejuvenation to slow or reverse aging. They emphasise bypassing regulatory bottlenecks, speeding up trial timelines, and collecting safety + efficacy data even among healthy individuals - all thanks to the less strict regulations in Prospera. Read more here.

  • Why it matters: Developing, testing, and proving new therapies safe and effective usually takes 10–15 years. Add the fact that aging itself isn’t classified as a disease, making the regulatory pathways even less straightforward, and it is no surprise that both biotech entrepreneurs and prospective patients are seeking ways to expedite these timelines. Nevertheless, SEZs like Prospera, Dubai Healthcare City or Singapore Biopolis do not have a long list of longevity companies to their name, suggesting that regulatory, capital, or infrastructure barriers remain substantial in these locations. Or that patients do not want to sacrifice trust for time.

Don’t want to miss any exclusive analysis? Subscribe for free!

🗓 Events & meetups (Europe-only)

Share this article with others who might benefit.

Share

💼 Longevity jobs (Europe-only)

Germany:

Rest of Europe:

Keep building the future of longevity - one week at a time.
Fabian

P.S. Want your open positions or events to be featured? Just send them my way by replying to this email.

]]><![CDATA[Last Week in Longevity #5 - $ 194M raised + 13.3% CAGR forecast]]>https://longevitybuilders.eu/p/last-week-in-longevity-5-194m-raisedhttps://longevitybuilders.eu/p/last-week-in-longevity-5-194m-raisedWed, 10 Sep 2025 08:23:45 GMT👋 Hi, I am Fabian, and welcome to my newsletter Last Week in Longevity. Every week, I track where the money, talent, and ideas are moving in the longevity business.

💸 Closed funding rounds

US$ 194M raised across 8 deals (↗️ +304% vs. US$ 48M across 6 deals last week)

NRG Therapeutics - US$ 68M Series B
The Stevenage-based (UK) company is trying to preserve mitochondrial health as a treatment for neurodegenerative diseases like ALS or Parkinson’s disease. Their small molecule inhibitors target the mitochondrial permeability transition pore (mPTP), a mechanism associated with cell death and neuroinflammation. Investors include, among others British Business Bank, SV Health Investors’ Dementia Discovery Fund (DDF), M Ventures, Novartis Venture Fund, and Criteria Bio Ventures. Learn more here: Company | Article

Epigenic Therapeutics - US$ 60M Series B
The 4-year-old Shanghai-based (CN) company is developing a way to turn off disease-related genes, not by cutting or editing DNA, but by using “epigenetic switches”. They are currently targeting high cholesterol (LDL) and a cure for chronic hepatitis B. The investment was led by Lapam Capital with support from current backers OrbiMed and Qiming Venture Partners. Learn more here: Company | Article

Congruence Therapeutics - US$ 32M
The 4-year-old Montreal-based (CA) drug development company is creating small molecules that act as repair kits for defective proteins, restoring their natural function. The funding round comes on the heels of advancing its genetic obesity drug into a Phase Ib clinical trial. Investors include, among others FSTQ, Amplitude Ventures, Lumira, BDC Capital’s Thrive Venture Fund, Investissement Quebec, OrbiMed, Silver Arc. Learn more here: Company | Article

Revalia Bio - US$ 14.5M Seed
The 2-year-old New Haven-based (US) company helps drug developers to test new therapies on real human organs in pre-clinical research. The organs used in the trials have been revived and sustained using proprietary perfusion technology and come from donors whose organs are not viable for transplant. Investors include America’s Frontier Fund, Sierra Ventures, and previous investors. Learn more here: Company | Article

Integra Therapeutics - US$ 12.6M Pre-Series A
The 5-year-old Barcelona-based (ES) company is developing a more precise gene writing technology (compared to CRISPR). The goal is to cure genetic, oncological and autoimmune diseases. Investors include EIC Fund (the venture arm of the European Innovation Council), Spain’s CDTI Innvierte, AdBio, Columbus, Invivo, and Takeda Ventures. Learn more here: Company | Article

NewDays - US$ 7M Seed
The 1-year-old Seattle-based (US) company launched Sunny, an AI companion that chats with people experiencing mild cognitive impairment and dementia to stimulate their mind - backed by strong clinical science and coupled with human clinician monitoring. The round was led by General Catalyst and Madrona. Learn more here: Company | Article

Minovia Therapeutics - US$ 350k Grant
The 13-year-old Haifa-based (IL) company is developing mitochondrial blood-based biomarkers that quantify mitochondrial content, quality, and function, to establish a standardised “MitoScore”. The research grant is sponsored by Countdown For A Cure, a foundation dedicated to accelerating mitochondrial research and medicine. Learn more here: Company | Article

Longevity.Technology - undisclosed amount
The 6-year-old London-based (UK) media company is running a longevity-focused news and data platform. The investment was led by Seveno Capital. Learn more here: Company | Article

🤑 Exits

Thrive acquires Bionic Health for an undisclosed amount
Started out as an “AI health clinic” in 2022, Bionic Health was acquired by Thrive, a telehealth company focused on medical weight loss and testosterone replacement therapy. Learn more here: Article

Want the full weekly funding database + exclusive analysis? Subscribe for free!

Want the full weekly funding database? Subscribe for free!

📰 Top longevity business news

  • Xi and Putin living forever?
    At a Beijing military parade, Presidents Xi Jinping and Vladimir Putin were overheard discussing organ transplantation, biotechnology, and even the prospect of living to 150 - framing extended lifespan as a realistic future. The exchange, captured via hot mic, offers a rare glimpse into how two long-tenured leaders think about pushing biological limits. Read more here.
    👉 Why it’s important:
    While not traditional business news, top-level political interest can accelerate longevity’s move into the mainstream. If Russia and China choose to pour money into “immortality for autocrats,” longevity research could see a wave of new state-backed investment.

  • Longevity Therapy Market forecast: 13.3% CAGR
    The global Longevity Therapy Market was valued at USD 19.4 billion in 2023, and is projected to grow to USD 59.7 billion by 2033. Read more here.

    👉 Why it’s important:
    Another market forecast in line with everyone’s gut feeling: How can slowing aging (and eventually reversing, as optimists would say) NOT be big business? What is striking is that the market size differs significantly from e.g. the UBS report forecasting for the Longevity Economy of USD 8tr by 2030 (up from USD 5.3tr in 2023). While I haven’t compared the methodologies, the trajectory signals an imminent transition from niche research into a mainstream market with serious demand from healthcare systems, insurers, governments, and investors looking to extend healthspan at scale.

  • The Food Supplement Market forecast: 8.4% CAGR
    The supplement market reached US$ 173 billion in 2022 and is projected to reach US$ 345 billion by 2031, with a robust CAGR of 8.4% from 2024 to 2031.
    👉 Why it’s important:
    Unlike many other parts of longevity protocols (be it gene therapies or just daily exercise), supplements are accessible, easy (no effort, just take a pill), cheap, and unregulated enough to hit the market fast. They serve as the entry point for consumers into the longevity ecosystem (e.g., collagen, NMN, spermidine, creatine). Growth to US$ 345B by 2031 validates that consumers are actively investing in preventive health and aging well.

  • Anti-aging claims outpacing science
    With clinics, supplements, and longevity interventions flooding the market promising to slow, halt, or even reverse aging, it is hard to tell which claims are evidence-based and which are marketing hype. Regulation regarding health claims exists, but it usually lags behind trends, making it essential for consumers to approach efficacy statements with caution. Read more here.

    👉 Why it’s important:
    In longevity, trust is everything - especially if the desired effect can not immediately be seen/felt by consumers. Overpromising may grab quick attention, but it risks long-term reputational damage. Sustainable growth depends on realistic messaging based on trusted data (while standardized, reliable aging biomarkers are still emerging). Nevertheless, I understand the temptation of simple, bold messaging to cut through the noise directly to the consumer’s heart…

Don’t want to miss any exclusive analysis? Subscribe for free!

🗓 Events & meetups (Europe-only)

Share this article with others who might benefit.

Share

💼 Longevity jobs (Europe-only)

Germany:

Rest of Europe:

Keep building the future of longevity - one week at a time.
Fabian

P.S. Want your open positions or events to be featured? Just send them my way by replying to this email.

]]><![CDATA[Last Week in Longevity #4 - $48M raised + The Smart Ring War]]>https://longevitybuilders.eu/p/last-week-in-longevity-4-48m-raisedhttps://longevitybuilders.eu/p/last-week-in-longevity-4-48m-raisedWed, 03 Sep 2025 09:27:26 GMT👋 Hi, I am Fabian, and welcome to my newsletter Last Week in Longevity. Every week, I track where the money, talent, and ideas are moving in the longevity business.

Let’s get started.

📰 Top longevity business news

  • The Smart Ring War is heating up: Oura, the maker of smart rings loved by many longevity enthusiasts, has won a decisive ITC ruling (U.S. International Trade Commission) that bans Ultrahuman and RingConn smart rings from the U.S. market, leveraging a newly issued patent on ring form factors. Samsung even filed a preemptive lawsuit over its Galaxy Ring (later dismissed), highlighting how seriously competitors take Oura’s IP strategy. With Ultrahuman now countersuing in India, smart rings are entering full-blown patent warfare. Read more here.
    👉 Why this is interesting:
    Patent wars mean wearables have matured: Oura is no longer a scrappy startup but a patent fortress with 100 granted and 270 pending patents. That is a lot of ‘ammunition’ to defend its territory in the billion $$$ wearables market and probably directly copied from the playbook their competitors like Samsung have used in the past (e.g. when suing Apple over the iPhone design).

  • McKinsey: Healthspan could add US$ 2T GDP. Biomedical interventions that affect the aging process and improve health outcomes could translate to as much as US$ 2 trillion in annual GDP uplift (globally). To accelerate progress in healthspan science, the report suggests the field could advance efforts across seven dimensions, including derisking investments by stronger collaboration between different types of investors with different skillsets, as well as the development of more practitioner talent. Read more here.
    👉 Why this is interesting:
    Reports by McK and the likes signal growing institutional recognition of healthspan as a strategic category. It elevates longevity from being a niche topic to a high-impact investment domain, mobilising regulators, investors, and biotech toward scalable health-extension solutions.

  • Portfolia launches its US$ 20m Women’s Health Fund IV. The fund targets underinvested yet impactful areas like fertility, menopause, cardiovascular health, nutrition, and longevity. The first investment of the fund was Gameto (stem cell-derived therapies for reproductive health), which we featured two weeks ago. Read more here.
    👉 Why this is interesting:
    For decades, clinical research defaulted to men, and results often fail to translate to women. Yet with 4 billion women globally, this is hardly a niche. The disconnect is stark: women’s health attracts just ~2% of venture funding, despite representing a $1T+ market (with female-focused longevity therapeutics already worth ~$20B).

  • ProLon released an updated iteration of its fasting-mimicking diet (a short-term, low-calorie diet designed to trigger fasting-like effects on the body without complete food restriction). The program consists of shelf-stable, ready-to-eat organic soups and teas while preserving its clinically validated FMD science. Read more here.
    👉 Why this is interesting:
    Fasting is hard. Humans are lazy and comfort-seeking. So how can companies help people get the metabolic/longevity benefits of fasting? They do what the food industry has already perfected: Packaged, ready-to-eat convenience food - this time just with reduced calories (but not a reduced price tag, of course).

  • St. Bernards opens Longevity Center in Jonesboro (USA), repurposing a previously unoccupied space in the existing hospital. Read more here.
    👉 Why this is interesting:
    While most longevity clinics have opened in big cities, Jonesboro has an estimated population of approximately 80k. If successful, this longevity center offers a blueprint for broader deployment of longevity-focused clinics.

  • 5 out of 7 days, people think about their weight, but 87% delay taking action due to life responsibilities. What sounds like a paradox was revealed by Pritikin Longevity Center survey. Read more here.
    👉 Why this is interesting:
    The disparity between health awareness and action reveals a major longevity-commercial opportunity: services and products must help people overcome their inner ‘demons’/inertia holding them back from desired change (see also ProLon above) and help to build healthy habits.

💸 Closed funding rounds

US$ 48M raised across 6 deals (↘️ down 69% from US$ 154M across 7 deals last week)

Leal Therapeutics - US$ 30M Series A
The 4-year-old Worcester-based (USA) company is developing therapeutics to correct metabolic imbalances in the brain, focusing on treating neurodegenerative and neuropsychiatric diseases. Transforming age-related neurodegeneration (e.g., ALS, Alzheimer’s) can extend healthy lifespan. Investors include SV Health Investors' Dementia Discovery Fund (DDF) as well as existing investors OrbiMed, Newpath Partners, Chugai Venture Fund, Euclidean Capital, and more. Learn more here: Company, Article

Therna - US$ 10M Seed
The San Francisco-based (USA) company, founded in 2020, is building generative AI models for decoding the language of RNA (claiming to be the largest RNA model to date). Using these models, the goal is programmable RNA therapeutics engineered for enhanced translation, durability, immune evasion, and precise tissue targeting. RNA medicines regulate protein production or deliver instructions for protein synthesis. Investors include: AIX Ventures, Pear VC, and Fusion Fund. Learn more here: Company, Article

Feel Goods - US$ 4.7M Seed
The West Hollywood-based (USA) company, founded in 2020, sells supplements for gut and immune health. The round was led by Cutting Horse, with participation from Adapt VC, SuperAngel.Fund, Air Ventures, TA Ventures, and OpenSky Ventures. Learn more here: Company, Article

Model Health - US$ 1M Pre-Seed
The 1-year-old Brussels-based (Belgium) company enables physical therapists and athletic trainers to capture and interpret lab-grade movement analysis using standard smartphone technology. The technology originated from research by co-founders Antoine Falisse (CEO) and Scott Uhlrich (CSO) at Stanford University, where it has already been adopted by more than 10,000 users in the academic community. APEX Capital led the round with participation from Syndicate One, LeanSquare, imec.istart, and various angel investors. Learn more here: Company, Article

One Stop Wellness - US$ 1M
The Texas-based (USA) company, founded in 2018, offers an on-demand health literacy platform that incentivises employees to adopt healthy habits with the goal to add up to 9.5 years to the lifespan of its users. The funding will help to launch an AI-powered food scanner, the first of its kind designed to recognise and analyse culturally relevant foods commonly eaten in Black and Caribbean communities. It is part of a broader mission to make health tools inclusive, data-driven, and accessible to those often overlooked in traditional wellness tech. Investors include Amazon’s Alexa Fund, Jumpstart Foundry, and several angel investors. Learn more here: Company, Article

Seluna - US$ 1M
The Glasgow-based (Scotland) company, founded in 2022, is developing AI-powered diagnostics for paediatric sleep disorders like sleep apnea. Left untreated, sleep apnea in children can impair neurocognitive development, mimic ADHD, and increase long-term risks of chronic neurological, cardiac, and metabolic disease. Investors include Gabriel Investment Syndicate, Scottish Enterprise, University of Strathclyde, and STAC Invest. Learn more here: Company, Article

Want the full weekly funding database + exclusive analysis? Subscribe for free!

🗓 Events & meetups (Europe-only)

Share this article with others who might benefit.

Share

💼 Longevity jobs (Europe-only)

Keep building the future of longevity - one week at a time.
Fabian

P.S. Want your open positions or events to be featured? Just send them my way by replying to this email.

]]><![CDATA[Last Week in Longevity #3 - $154M Raised + OpenAI's latest longevity contribution]]>https://longevitybuilders.eu/p/last-week-in-longevity-3-154m-raisedhttps://longevitybuilders.eu/p/last-week-in-longevity-3-154m-raisedWed, 27 Aug 2025 11:33:48 GMT👋 Hi, I am Fabian, and welcome to my newsletter Last Week in Longevity. Every week, I track where the money, talent, and ideas are moving in the longevity business.

Here’s what you need to know this week:

  • Top longevity business news (international),

  • Closed funding rounds (international),

  • Events & meetups (Europe-only), and

  • Longevity jobs (Europe-only).

Let’s get started.

📰 Top longevity business news

  • Longevity clinic SHA has integrated WHOOP wearables into its program, combining real-time recovery, sleep, and strain data with cellular therapies, precision nutrition, and diagnostics. Read more here.
    👉 Why this is interesting:
    If the last 20 years have proved one thing: You can build hugely successful companies around data. After all, “data is the oil of the 21st century”. And the amount of data WHOOP & co are collecting is crazy, with still so many untapped use cases outside of their own app ecosystems. From a strategic perspective, longevity clinics are early adopters and will become proving grounds for wearable data. If SHA validates outcomes with WHOOP, expect insurers (who care about lowering costs; see example last week) and healthcare providers (who care about delivering better outcomes at scale) to follow.

  • OpenAI built GPT-4b micro, a downsized model specialised for protein engineering, in collaboration with longevity startup Retro Biosciences. The model designed new variants of the Yamanaka factors, proteins used to reprogram adult cells into stem cells (e.g. used to replace damaged tissues or used in personalised cell therapies), achieving 50-fold higher efficiency in lab tests. Read more here.
    👉 Why this is interesting:
    This gives us early evidence for what we are all hoping for: AI has the potential to accelerate life sciences and longevity research so that death becomes optional - and all during our own lifetime.

  • The Japanese company AutoPhagyGO, a XPRIZE semi-finalist, focuses on harnessing autophagy to demonstrate rejuvenation in muscle, cognition, and immunity. Therefore, they blend Nobel-backed autophagy science with Japan’s cultural lifestyle heritage to create safe, measurable interventions for healthy aging, based on wearable tools, dietary strategies, and supplements. Their flagship Awabancha extract extended lifespan in C. elegans by 14%. Read more here.
    👉 Why this is interesting:
    Japan is a natural hub for autophagy innovation: the 2016 Nobel Prize in Medicine for its discovery went to Japanese biologist Yoshinori Ohsumi. If AutoPhagyGO succeeds in quantifying human autophagy biomarkers without the need for traditional wet labs, it creates an entirely new diagnostics category, which could become the “CGM for cellular cleanup”. Whoever validates individual autophagy metrics has the chance to own the personalisation layer of nutrition and supplements, an untapped market that dwarfs generic hacks like intermittent fasting or keto.

  • The first longevity clinic opened in India. Read more here.
    👉 Why this is interesting:
    Last week, we discussed the emergence of longevity clinics “on every corner”. It is great to see that this trend is not limited to North America and Europe.

  • Aubrai, a blockchain-native AI agent, is transforming longevity research through AI-powered hypothesis generation, DAO governance, and tokenised intellectual property (IP). By converting validated discoveries into IP-tokens licensed to biotech firms and returning proceeds to researchers and AUBRAI token holders, the startup is trying to bridge the “Valley of Death” in longevity research. Read more here.
    👉 Why this is interesting:
    While this article feels very buzzword-heavy, Aubrai tackles a real problem: research funding. Not all projects appeal to conventional VC or philanthropic gatekeepers, and projects might want to seek capital elsewhere. Nonetheless, DeSci (decentralised science) is not new (e.g. longevity-focused VitaDAO), so let’s see if throwing agentic AI into the mix will help it to become more mainstream. If it really helps to accelerate discoveries and cuts validation timelines by up to 70% (!), it should have a real chance.

💸 Closed funding rounds

US$ 154M raised across 7 deals (↘️ down 40% from US$ 258M across 8 deals last week)

Twin Health - US$ 53M Series E
The Mountain View-based (USA) company empowers customers to address the root causes of metabolic conditions (like obesity or type 2 diabetes), using a real-time model (digital twin) of their unique metabolism. Using sensors and wearables to feed the digital twin, you can get insights and professional help to optimise your metabolic health. On the heels of their near-unicorn funding round (US$ 950M valuation), they published a study that shows that 71% of participants using the digital twin lowered their blood sugar level and were frequently able to stop using medications. Maj Invest led the round, with participation from existing investors, including Iconiq and Temasek. Learn more here: Company, Article

Wellth - US$ 36M Series C
The Los Angeles-based (USA) company provides “high‑risk populations” (e.g. patients) a mobile-first behavior-change platform delivering daily motivation to drive adherence to care plans. Wellth uses behavioral economics and financial incentives to encourage members to complete daily healthy actions like taking medications, checking blood pressure, measuring glucose, and showing up to appropriate preventative care visits, thereby helping to build lasting habits that lead to better health outcomes and measurable ROI for partners. Investors include: Mercato Partners, FCA Venture Partners, Comcast Ventures, and existing investors SignalFire, NY Life, and CD-Venture. Learn more here: Company, Article

Debut - US$ 20M
The San Diego-based (USA) company develops novel ingredients and formulations for skin longevity, using its own AI-based ingredient discovery platform. Funding will be used to screen more than 50 billion ingredients and their impact on skin health and longevity, as well as expanding into Asia. Investors include Fine Structure Ventures, EDBI, Wealthberry, BOLD (the venture fund of L'Oréal), among others. Learn more here: Company, Article

Sava - US$ 19M Series A
The London-based (UK) company is developing a wearable microsensor platform enabling real‑time, multi‑molecule detection, starting with painless continuous glucose monitoring (CGM) and expanding to broader biomarkers. The funding will pave the way for regulatory approval and commercialisation of the new wearable. Investors include Norrsken VC, JamJar Investments, True Global, Italian Founders Fund, Athletico Ventures, and Exceptional Ventures. Learn more here: Company, Article

MORROW - US$ 15.6M
The Singapore-based company is building a longevity clinic, intending to be more affordable for a wider customer base in helping them to adopt a healthy lifestyle through personalised roadmaps supported by a team of professionals and coaches. The goal is to open several locations around the globe, with a pledged investment of US$ 156M. So far, it seems entrepreneur Allen Law is financing the venture by himself.
Learn more here: Company, Article

Sleep.ai - US$ 5.5M
The San Diego-based (USA) company offers a sleep intelligence platform designed to generate advanced sleep insights, used by third-party products and services, as well as its own B2C app. Investors include Treasure Coast Ventures, Nurture Ventures, and more. Learn more here: Company, Article

Molecular You - US$ 5M Series A
The Vancouver-based (Canada) company focuses on health insights based on blood biomarker testing. They work with clinics as well as sell directly to individuals. The round was led by Voloridge Health, Dynamic Leap, and others. Learn more here: Company, Article

Want the full weekly funding database + exclusive analysis? Subscribe for free!

🗓 Events & meetups

Share this article with others who might benefit.

Share

💼 Longevity jobs

Keep building,
Fabian

P.S. Got feedback, fun ideas, or longevity-related news? I would love to hear from you - just reach out by replying to this email.

]]><![CDATA[Last Week in Longevity #2]]>https://longevitybuilders.eu/p/last-week-in-longevity-2https://longevitybuilders.eu/p/last-week-in-longevity-2Wed, 20 Aug 2025 08:12:15 GMTHi friends 👋,

Here is your weekly digest of everything that happened in Longevity last week. We will cover:

  • Top longevity business news (international),

  • Closed funding rounds (international),

  • Events & meetups (Europe-only), and

  • Longevity jobs (Europe-only).

Let’s get started.

📰 Top longevity business news

  • Longevity.Technology has unveiled the “Longevity Clinics World” directory to connect more than 350 validated longevity clinics globally with potential clients. Read more here.
    Why this is interesting: With longevity clinics popping up on “every corner”, finding the right one for you based on service portfolio, location, and price doesn’t get easier. And how are consumers able to judge and compare the quality of all providers? Therefore, a platform that truly allows comparing providers and validates clinics (instead of being just a lead source for clinic providers), builds trust and is a good thing for consumers.

  • Blood panel startup Superpower is cutting its price by 60%, so you can get 100+ blood biomarkers tested for USD 199. Read more here.
    Why this is interesting: With so many new entrants to this market and a hard-to-differentiate diagnostic side of the business (can you credibly differentiate on quality? Most choose the path of simply adding MORE biomakers), this part of the business feels like it is getting commoditised. While it is great for customers when it comes to prices, companies will continue to focus on building value-added services like (personalised) supplements, AI health concierge etc., to differentiate. And it makes sense, because getting the data is just the beginning, and what you do with it is where the progress (or dare I say "magic”?) happens.

  • Danone’s OIKOS has launched OIKOS FUSION, a cultured dairy drink with a patented blend whey protein, leucine, and vitamin D, to help build and retain muscle mass during weight loss, especially for GLP‑1 users. Read more here.
    Why this is interesting: Anyone who has ever tried to lose weight without losing lean muscle mass knows the struggle. While the need isn’t new, and you can clearly manage it without another dairy drink (and I am not sure what they even patented), I think targeting GLP-1 users to support them on their journey is great from a marketing perspective.

  • Seragon Biosciences introduced Enlivien, a new sleep and longevity supplement that combines anti‑oxidative, anti‑inflammatory, and mitochondrial support compounds to counteract damage from chronic sleep deprivation. The formulation is backed by Harvard research linking sleep loss to oxidative gut and neural damage, offering a molecularly targeted longevity solution. Read more here.
    Why this is interesting: In our busy lives, prioritising sleep is not always possible (shout-out to all parents), so if there is a supplement to reduce the negative side-effects, supported by proper studies, sign me up.

  • Life insurance firm Ethos and longevity company Lifeforce have teamed up and allow Ethos’ policyholders to access Lifeforce’s longevity platform. Read more here.
    Why this is interesting: This collaboration signals a novel cross‑industry approach to longevity services by aligning insurance with healthy‑living engagement.

💸 Closed funding rounds

Eight Sleep - US$ 100M Series D
The New York-based (USA) company offers AI-powered sleep tech products (think: smart mattress and blanket) that promise to transform your bed into a preventive health device that can monitor, analyse, and enhance your sleep. Investors include: HSG, Valor Equity Partners, Founders Fund, Y Combinator, and others. Learn more here: Company, Article

Gameto - US$ 44M Series C
The Austin-based (USA) company develops stem cell-derived therapies for reproductive health. The Series C funding enables Gameto to complete the ongoing Phase 3 trial for its lead program, Fertilo, and file for regulatory approvals globally. Investors include: Overwater Ventures, with participation from Insight Partners, RA Capital, Two Sigma Ventures and others. Learn more here: Company, Article

Jocasta Neuroscience - US$ 35M Series A
The Scottsdale-based (USA) company is developing its proprietary klotho protein therapeutic, JN-0413, designed to replenish declining klotho levels, aimed at managing cognitive impairment linked to neurodegenerative diseases. Research in animals has shown that low levels accelerate aging and shorten lifespan, while elevated levels can extend life by up to 30 percent in certain experiments. Investors include Bain Capital, First Round, Khosla Ventures and Valor Equity Partners. Learn more here: Company, Article

August Health - US$ 29M Series B
The San Francisco-based (USA) company operates an Electronic Health Record (EHR) platform for senior living operators. Investors include Base10 Partners, General Catalyst, and Matrix Partners. Learn more here: Company, Article

Oneskin - US$ 20M Series A
The San Francisco-based (USA) company focuses on skin longevity, built around its proprietary peptide, OS-01, which supposedly reduces skin's biological age by improving skin barrier, supporting DNA damage repair, and preventing the accumulation of aged cells. The round was led by Prelude Growth Partners. Learn more here: Company, Article

Fountain Life - US$ 18M Series B
The Orlando-based (USA) company, which was co-founded by Tony Robbins, operates four longevity centres offering preventative diagnostics. The round was led by EOS Ventures, and existing shareholders. Learn more here: Company, Article

Isaac Health - US$ 10.5M Series A
The New York-based (USA) company offers a platform focused on screening, assessing, treating, and providing care management for brain health and dementia. Investors include Flare Capital Partners, Black Opal Ventures, and Industry Ventures. Learn more here: Company, Article

VentriJect - € 1.7M Series B
The Copenhagen-based (Denmark) company is a spinout from Aalborg University, which developed and sells a CE-marked medical device for VO₂max measurement for fitness and medical professionals. Investors include the Export and Investment Fund of Denmark (EIFO), HardTech Innovation Hub, and Investo Capital. Learn more here: Company, Article

Thanks for reading Longevity Builders EU! Subscribe for free to receive new posts and support my work.

🗓 Events & meetups

Thanks for reading Longevity Builders EU! This post is public so feel free to share it.

Teilen

💼 Longevity jobs

Keep building,
Fabian

P.S. Got feedback, fun ideas, or longevity-related news? I would love to hear from you - just reach out by replying to this email.

]]><![CDATA[Last Week in Longevity #1]]>https://longevitybuilders.eu/p/last-week-in-longevity-1https://longevitybuilders.eu/p/last-week-in-longevity-1Wed, 13 Aug 2025 15:25:25 GMTHi friends 👋,

Here is your weekly digest of everything that happened in Longevity last week. We will cover:

  • Top longevity business news (international),

  • Closed funding rounds (international),

  • Events & meetups (Europe-only), and

  • Longevity jobs (Europe-only).

Let’s get started.

📰 Top longevity business news

  • HeartFlow’s IPO sees 50% surge on Nasdaq debut. The company created 3D models of patient’s hearts using AI for better CAD treatment. AInvest has more.

  • A baby has been born from an embryo that is over 30 years old. It’s not the same as reviving someone after cryopreservation, but maybe scientists can learn something from it nevertheless to advance this goal. Read more here.

💸 Closed funding rounds

SetPoint Medical - US$ 115M Series D
The Valencia-based (USA) company develops and produces implantable devices that stimulate the vagus nerve to reduce inflammation and treat chronic autoimmune diseases such as rheumatoid arthritis. The company won FDA approval for the system last month. Investors include. Elevage Medical Technologies and Ally Bridge Group. Learn more here: Company, Article

Loyal - US$ 45M Series B
The San Francisco-based (USA) company is developing medicines to extend dog lifespan. Investors include Bain Capital, First Round, Khosla Ventures and Valor Equity Partners. Learn more here: Company, Article

Everlab - US$ 10M Series B
The Melbourne-based (Australia) company operates longevity clinics and will use the cash injection for international expansion. Investors include Left Lane Capital and AfterWork Ventures. Learn more here: Company, Article

Blue Longevity Clinic - € 2M Seed
The Sofia-based (Bulgaria) company is planning to launch longevity health centers in Greece, Turkey, and Bulgaria. Investors include Eleven Ventures and Sofia Angels Ventures. Learn more here: Company, Article

Thanks for reading Longevity Builders EU! Subscribe for free to receive new posts and support my work.

🗓 Events & meetups

💼 Longevity jobs

Fabian

P.S. Got feedback, fun ideas, or longevity-related news? I would love to hear from you - just reach out by replying to this email.

Thanks for reading Longevity Builders EU! This post is public so feel free to share it.

Teilen

]]>